Viread Product Monograph

SUMMARY PRODUCT INFORMATION

Route of Administration Dosage Form/Strength

Clinically Relevant Nonmedicinal Ingredients^a

Oral

Tablet

tenofovir disoproxil fumarate

300 mg

lactose monohydrate, pregelatinized starch (gluten free)

^a For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING section.

INDICATIONS AND CLINICAL USE

HIV-1 Infection

VIREAD^® (tenofovir disoproxil fumarate [TDF]) is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in patients 12 years of age and older.

Chronic Hepatitis B

VIREAD is indicated for the treatment of chronic hepatitis B infection in patients 18 years of age and older, with:

• Compensated liver disease, with evidence of active viral replication, with elevated serum alanine aminotransferase (ALT) levels or evidence of fibrosis (based on liver biopsy or a noninvasive procedure);
• Evidence of lamivudine-resistant hepatitis B virus; or
• Decompensated liver disease.

Geriatrics (≥65 years of age)

Clinical studies of VIREAD did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Pediatrics (12 to <18 years of age)

The safety and efficacy of VIREAD in adolescent patients aged 12 to <18 years is supported by data from one randomized study in which VIREAD was administered to HIV-1 infected treatment experienced subjects. In this study, the pharmacokinetic profile of VIREAD was similar to that found to be safe and effective in adult populations.

Safety and efficacy in pediatric patients less than 12 years of age have not been established.

CONTRAINDICATIONS

VIREAD is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the product. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

• Lactic Acidosis and Severe Hepatomegaly with Steatosis

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, alone or in combination with other antiretrovirals (see WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic).

• Post-Treatment Exacerbation of Hepatitis B

Severe acute exacerbations of hepatitis have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VIREAD. If appropriate, resumption of anti-hepatitis B therapy may be warranted (see WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic).

• Nephrotoxicity

Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of VIREAD during clinical practice (see WARNINGS AND PRECAUTIONS, Renal).

General

For the effect of coadministered drugs, see DRUG INTERACTIONS section.

Clinical studies in HIV-infected patients have demonstrated that certain regimens that only contain three nucleoside reverse transcriptase inhibitors (NRTI) are generally less effective than triple drug regimens containing two NRTIs in combination with either a non-nucleoside reverse transcriptase inhibitor or a HIV-1 protease inhibitor. In particular, early virological failure and high rates of resistance mutations have been reported. Triple nucleoside regimens

should therefore be used with caution. Patients on a therapy utilizing a triple nucleoside-only regimen should be carefully monitored and considered for treatment modification.

VIREAD should not be used in combination with the following:

• Products containing TDF (ATRIPLA^®, COMPLERA^®, STRIBILD ^® or

  TRUVADA^®).

• Products containing tenofovir alafenamide (DESCOVY^®, or GENVOYA^®,

  ODEFSEY™, or VEMLIDY™).

• adefovir dipivoxil (HEPSERA^®).

Bone Effects

In HIV-infected patients treated with VIREAD in Study 903 through 144 weeks, decreases from baseline in bone mineral density (BMD) were seen at the lumbar spine and hip in both VIREAD and stavudine treatment arms of the study and significantly greater decreases were seen in the lumbar spine measurement in the VIREAD group relative to the stavudine group. Clinically relevant fractures were reported in both treatment groups. Increases in biochemical markers of bone metabolism (serum bone-specific alkaline phosphatase, serum osteocalcin, serum C-telopeptide, and urinary N-telopeptide) were observed, suggesting increased bone turnover. Except for bone specific alkaline phosphatase, these changes resulted in values that remained within the normal range (see ADVERSE REACTIONS, HIV-1 Infection, Study 903). In a clinical study of HIV-1 infected adolescent subjects (Study 321), bone effects were similar to adult subjects. Under normal circumstances, BMD increases rapidly in adolescents. In this study, the mean rate of bone gain was less in the VIREAD-treated group compared to the placebo group. Six VIREAD treated adolescents and one placebo treated adolescent had significant (>4%) lumbar spine BMD loss in 48 weeks. Among 28 subjects receiving 96 weeks of VIREAD, Z-scores declined by −0.341 for lumbar spine and −0.458 for total body. Skeletal growth (height) appeared to be unaffected. Markers of bone turnover in VIREAD-treated adolescents increased bone turnover, consistent with the effects observed in adults. The effects of VIREAD-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown.

Cases of osteomalacia (associated with proximal renal tubulopathy and infrequently contributing to fractures) have been reported in association with the use of VIREAD (see ADVERSE REACTIONS, Post Market Adverse Drug Reactions).

Bone monitoring should be considered for patients who have a history of pathologic bone fracture or are at risk for osteopenia, such as subjects co-infected with HBV and HIV or subjects on extended corticosteroid therapy. Although the effect of supplementation with calcium and vitamin D was not studied, such supplementation may be beneficial for all patients. If bone abnormalities are suspected then appropriate consultation should be obtained.

Carcinogenesis, Mutagenesis, Impairment of Fertility

TDF did not show any carcinogenic potential in a long-term oral carcinogenicity study in rats. A long-term oral carcinogenicity study in mice showed a low incidence of duodenal tumors, considered likely related to high local concentrations in the gastrointestinal tract at the high dose of 600 mg/kg/day. The mechanism of tumor formation in mice and potential relevance for humans are uncertain.

TDF was mutagenic in the in vitro mouse lymphoma assay and negative in an in vitro bacterial mutagenicity test (Ames test). In an in vivo mouse micronucleus assay, TDF was negative at doses up to 2000 mg/kg when administered orally to male mice.

There were no effects on fertility, mating performance or early embryonic development when TDF was administered at 600 mg/kg/day to male rats for 28 days prior to mating and to female rats for 15 days prior to mating through day seven of gestation. There was, however, an alteration of the estrous cycle in female rats. A dose of 600 mg/kg/day is equivalent to 19 times the human dose based on body surface area comparisons.

Drug Interactions

Use with Certain HCV Regimens

Tenofovir exposure is increased when VIREAD is coadministered with HARVONI^® (ledipasvir/sofosbuvir), EPCLUSA^® (sofosbuvir/velpatasvir), or VOSEVI™ (sofosbuvir/velpatasvir/voxilaprevir). Patients receiving a regimen containing TDF concomitantly with HARVONI, EPCLUSA, or VOSEVI, particularly those at increased risk for renal dysfunction, should be monitored for TDF-associated adverse reactions (see DRUG INTERACTIONS).

Use with Didanosine

Pharmacokinetic studies have shown that coadministration of didanosine and TDF results in 40-60% increase in C_max and AUC of didanosine (see Table 12). The mechanism of this interaction is unknown. Increases in didanosine concentrations of this magnitude could potentiate didanosine-associated adverse events, including pancreatitis, lactic acidosis, and neuropathy. In addition, suppression of CD4 counts has been observed in patients receiving TDF with didanosine at a dose of 400 mg daily (see DRUG INTERACTIONS).

Endocrine and Metabolism

Serum Lipids and Blood Glucose

Serum lipid and blood glucose levels may increase during antiretroviral therapy. Disease control and life style changes may also be contributing factors. Consideration should be given to the measurement of serum lipids and blood glucose. Lipid disorders and blood glucose elevations should be managed as clinically appropriate.

Hepatic/Biliary/Pancreatic

Lactic Acidosis/Severe Hepatomegaly with Steatosis

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues, including TDF, alone or in combination with other antiretrovirals in the treatment of HIV infection. A majority of these cases have been reported in women. Obesity and prolonged nucleoside exposure may be risk factors. Caution should be exercised when administering nucleoside analogs to any patient, and particularly to those with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with VIREAD should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase levels).

Pancreatitis

Pancreatitis has occurred during therapy with combination regimens that included VIREAD. Caution should be used when administering nucleoside analogues (including VIREAD) to patients with a history of pancreatitis or risk factors for the development of pancreatitis. Therapy should be suspended in patients with suspected pancreatitis.

Hepatic Impairment

Tenofovir and tenofovir disoproxil are not metabolized by liver enzymes. Clinically relevant pharmacokinetic changes in patients with hepatic impairment are not observed. Therefore, no dose adjustment is required in patients with hepatic impairment. The safety and efficacy of TDF has not been established or specifically studied in patients with underlying liver disorders. Patients with chronic hepatitis B or C and treated with antiretroviral therapy are at increased risk for severe and potentially fatal hepatic adverse events. In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.

Exacerbation of Hepatitis After Discontinuation of Treatment

Discontinuation of anti-HBV therapy, including VIREAD, may be associated with severe acute exacerbations of hepatitis. Patients infected with HBV who discontinue VIREAD should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate, resumption of anti-hepatitis B therapy may be warranted. In patients with advanced liver disease or cirrhosis, post-treatment exacerbation of hepatitis may lead to hepatic decompensation. Therefore, in these patients, discontinuation of treatment without initiation of alternative anti-hepatitis B therapy is not recommended.

Immune

Immune Reconstitution Inflammatory Syndrome

During the initial phase of treatment, HIV-infected patients responding to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (such as MAC, CMV, PCP, and TB), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment and sometimes may be an atypical presentation.

Angioedema

Cases of angioedema have been reported in patients taking TDF (see ADVERSE REACTIONS, Post Market Adverse Drug Reactions).

Renal

Nephrotoxicity

Tenofovir is principally eliminated by the kidney. Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia) has been reported with the use of VIREAD in clinical practice. The majority of these cases occurred in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents; however, some cases occurred in patients without identified risk factors (see ADVERSE REACTIONS, Post Market Adverse Reactions and DRUG INTERACTIONS).

It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy and as clinically appropriate during therapy with VIREAD. Routine monitoring of calculated creatinine clearance, serum phosphorus, urine glucose, and urine protein should be performed in patients at risk for renal impairment, including patients who have previously experienced renal events while receiving HEPSERA.

Particular caution should be exercised when administering VIREAD to patients with known risk factors for renal disease and a history of renal dysfunction; however, cases of renal failure have also been reported in patients with no known risk factors. VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent.

Dosing interval adjustment is required in all patients with creatinine clearance <50 mL/min (see DOSAGE AND ADMINISTRATION, Dose Adjustment for Renal Impairment). The safety and efficacy of these dosing interval adjustment recommendations have not been clinically evaluated; therefore, clinical response to treatment and renal function should be

closely monitored in these patients. The potential benefit of VIREAD therapy should be assessed against the potential risk for renal toxicity.

Special Populations

Patients with HIV and Hepatitis B Virus Coinfection

Due to the risk of development of HIV resistance, VIREAD should only be used in HIV and HBV coinfected patients as part of an appropriate antiretroviral combination therapy.

HIV antibody testing should be offered to all HBV-infected patients before initiating therapy with VIREAD. It is also recommended that all patients with HIV be tested for the presence of chronic hepatitis B before initiating treatment with VIREAD.

Pregnant Women

There are no adequate and well-controlled studies in pregnant women. Reproduction studies have been performed in rats and rabbits at doses up to 14 and 19 times the human dose based on body surface area comparisons and revealed no evidence of impaired fertility or harm to the fetus due to tenofovir. Reduced pup body weights, survival, and delay in sexual maturation was observed in a peri- and postnatal toxicity study in rats at the maternally toxic doses of 450 and 600 mg/kg (approximately 14 and 19 times the human dose based on body surface area comparisons). Because animal reproduction studies are not always predictive of human response, TDF should be used in pregnant women only if the potential benefits outweigh the potential risks to the fetus.

Antiretroviral Pregnancy Registry

To monitor fetal outcomes of pregnant women exposed to ART including VIREAD, an Antiretroviral Pregnancy Registry has been established. Healthcare providers are encouraged to register patients by calling (800)-258-4263.

Nursing Women

HIV and HBV infected women should not breastfeed to avoid risking postnatal transmission of HIV-1 and HBV. In humans, samples of breast milk obtained from five HIV-1 infected mothers show that tenofovir is secreted in human milk at low levels (estimated neonatal concentrations 128 to 266 times lower than the tenofovir IC₅₀). Tenofovir-associated risks, including the risk of developing viral resistance to tenofovir, in infants breastfed by mothers being treated with TDF are unknown. Mothers should be instructed not to breastfeed if they are receiving VIREAD because of both the potential for HIV-1 and HBV transmission and the potential for serious adverse reactions in nursing infants.

Pediatrics

The safety and efficacy of VIREAD in HIV adolescent patients aged 12 to <18 years is supported by data from one randomized study in which VIREAD was administered to HIV-1 infected treatment experienced subjects. In this study, the pharmacokinetic profile of VIREAD was similar to that found to be safe and effective in adult populations.

Safety and efficacy in patients less than 12 years of age have not been established.

Geriatric

Clinical studies of VIREAD did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for the elderly patient should be cautious, keeping in mind the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

ADVERSE REACTIONS

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

HIV-1 Infection

Clinical Trials: More than 12,000 patients have been treated with VIREAD alone or in combination with other antiretroviral medicinal products for periods of 28 days to 215 weeks in Phase 1-3 clinical trials and expanded access studies. A total of 1,544 patients have received VIREAD 300 mg once daily in Phase 1-3 clinical trials; over 11,000 patients have received VIREAD in expanded access studies.

Treatment-Experienced Adult Patients

Study 907 - Treatment-Emergent Adverse Events: The most common adverse events that occurred in patients receiving VIREAD with other antiretroviral agents in clinical trials were mild to moderate gastrointestinal events, such as nausea, diarrhea, vomiting and flatulence. Less than 1% of patients discontinued participation in the clinical studies due to gastrointestinal adverse events (Study 907).

A summary of treatment-emergent adverse events that occurred during the first 48 weeks of Study 907 is provided in Table 1.

Table 1. Selected Treatment-Emergent Adverse Events (Grades 2–4)

Reported in ≥ 3% in Any Treatment Group in Study 907 (0-48 weeks)

Placebo Crossover to

VIREAD

(N=170)

(Week 24–48)

Body as a Whole

Asthenia

1%

Pain

4%

Headache

2%

Abdominal pain

6%

Back pain

2%

Chest pain

2%

Fever

2%

Digestive System

Diarrhea

11%

Nausea

7%

Vomiting

5%

Anorexia

1%

Dyspepsia

2%

Flatulence

1%

Respiratory

Pneumonia

2%

Nervous System

Depression

4%

Insomnia

4%

Peripheral neuropathy¹

2%

Dizziness

1%

Skin and Appendage

Rash event²

1%

Sweating

1%

Musculoskeletal

Myalgia

1%

Metabolic

Weight loss

2% 1 Peripheral neuropathy includes peripheral neuritis and neuropathy.

2 Rash event includes rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, and pustular rash.

Laboratory Abnormalities: Laboratory abnormalities observed in this study occurred with similar frequency in the VIREAD and placebo-treated groups. A summary of Grade 3 and 4 laboratory abnormalities is provided in Table 2.

Table 2. Grade 3/4 Laboratory Abnormalities Reported in ≥ 1% of

VIREAD-Treated Patients in Study 907 (0–48 weeks)

Placebo Crossover to

VIREAD

(N=170)

(Week 24–48)

(%)

Any ≥ Grade 3 Laboratory Abnormality

34%

Triglycerides (>750 mg/dL)

9%

Creatine Kinase

(M: >990U/L) (F: >845 U/L)

12%

Serum Amylase (>175 U/L)

6%

Urine Glucose (≥3+)

2%

AST

(M: >180 U/L) (F: >170 U/L)

5%

ALT

(M: >215 U/L) (F: >170 U/L)

5%

Serum Glucose (>250 U/L)

3%

Neutrophils (<750/mm³)

1%

Treatment-Naïve Adult Patients

Study 903 - Treatment-Emergent Adverse Events: The adverse reactions seen in a double-blind active-controlled study in which 600 treatment-naïve patients received VIREAD (N=299) or stavudine (N=301) in combination with lamivudine and efavirenz for 144 weeks (Study 903) were generally consistent, with the addition of dizziness, with those seen in treatment-experienced patients (Table 3).

Mild adverse events (Grade 1) were common with a similar incidence in both arms and included dizziness, diarrhea and nausea.

Table 3. Selected Treatment-Emergent Adverse Events (Grades 2–4)

Reported in ≥ 5% in Any Treatment Group in Study 903 (0–144 Weeks)

VIREAD + 3TC + EFV

N=299

d4T + 3TC + EFV

N=301

Body as a Whole

Headache 14% 17%

Pain 13% 12%

Back pain 9% 8%

Fever 8% 7%

Abdominal pain 7% 12%

Asthenia 6% 7%

Digestive System

Diarrhea 11% 13%

Nausea 8% 9%

Vomiting 5% 9%

Dyspepsia 4% 5%

Metabolic Disorders

Lipodystrophy 1% 8%

Musculoskeletal

Arthralgia 5% 7%

Myalgia 3% 5%

Nervous System

Depression 11% 10%

Anxiety 6% 6%

Insomnia 5% 8%

Dizziness 3% 6%

Peripheral neuropathy¹ 1% 5%

Respiratory

Pneumonia 5% 5%

Skin and Appendages

Rash event² 18% 12%

1 Peripheral neuropathy includes peripheral neuritis and neuropathy.

2 Rash event includes rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, and pustular rash.

Laboratory Abnormalities: With the exception of triglyceride elevations that were more common in the stavudine group (14%) compared with VIREAD (3%), laboratory

abnormalities observed in this study occurred with similar frequency in the VIREAD and stavudine treatment arms. A summary of Grade 3 and 4 laboratory abnormalities is provided in Table 4.

Table 4. Grade 3/4 Laboratory Abnormalities Reported in ≥1% of

VIREAD-Treated Patients in Study 903 (0–144 Weeks)

VIREAD + 3TC + EFV

N=299

d4T + 3TC + EFV

N=301

Any ≥ Grade 3 Laboratory Abnormality 36% 42%

Fasting Cholesterol (>240 mg/dL) 19% 40%

Creatine Kinase

(M: >990 U/L)

(F: >845 U/L)

12% 12%

Serum Amylase (>175 U/L) 9% 8%

AST

(M: >180 U/L)

(F: >170 U/L)

5% 7%

ALT

(M: >215 U/L)

(F: >170 U/L)

4% 5%

Hematuria (>100 RBC/HPF) 7% 7%

Neutrophil (<750/mm³) 3% 1%

Fasting Triglyceride (>750 mg/dL) 1% 9%

In Study 903 through 144 weeks, decreases from baseline in bone mineral density (BMD) were seen at the lumbar spine and hip in both arms of the study. At Week 144, there was a significantly greater mean percentage decrease from baseline in BMD at the lumbar spine in patients in the VIREAD group compared with patients in the stavudine group (see Table 5). In both groups, the majority of the reduction in BMD occurred in the first 24–48 weeks of the study and this reduction was sustained through Week 144. Twenty-eight percent of VIREAD-treated patients vs. 21% of the stavudine-treated patients lost at least 5% of BMD at the spine or 7% of BMD at the hip. Clinically relevant fractures (excluding fingers and toes) were reported in 4 patients in the VIREAD group and 6 patients in the stavudine group. In addition, there were significant increases in biochemical markers of bone metabolism (serum bone-specific alkaline phosphatase, serum osteocalcin, serum C-telopeptide, and urinary N-telopeptide) in the VIREAD group relative to the stavudine group, suggesting increased bone turnover. Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher in the VIREAD group. Except for bone specific alkaline phosphatase, these changes resulted in values that remained within the normal range. The effects of VIREAD-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown.

Table 5. Changes in Bone Mineral Density in Study 903

Mean Percent Change (± SD) to Week 144 in BMD

VIREAD + 3TC+ EFV d4T + 3TC +EFV

Lumbar Spine –2.2% ± 3.9 –1.0% ± 4.6

Hip –2.8% ± 3.5 –2.4% ± 4.5

Study 934 - Treatment Emergent Adverse Events: Study 934 was an open-label active-controlled study in which 511 antiretroviral-naïve patients received either VIREAD + EMTRIVA (emtricitabine) administered in combination with efavirenz (N=257) or Combivir^® (lamivudine/zidovudine) administered in combination with efavirenz (N=254). Adverse events observed in this study were generally consistent with those seen in other studies in treatment-experienced or treatment-naïve patients (Table 6).

Table 6. Selected Treatment-Emergent Adverse Events (Grades 2–4)

Reported in ≥ 3% in Any Treatment Group in Study 934 (0-48 weeks)

VIREAD+FTC+ EFV

N=257

AZT/3TC+EFV

N=254

Blood and Lymphatic System Disorders

< 1% 5% Anemia

Gastrointestinal Disorder

Diarrhea 7% 4%

Nausea 8% 6%

Vomiting 1% 4%

General Disorders and Administration Site Condition

7% 6% Fatigue

Infections and Infestations

Sinusitis 4% 2%

Upper respiratory tract infections 3% 3%

Nasopharyngitis 3% 1%

Nervous System Disorders

Somnolence 3% 2%

Headache 5% 4%

Dizziness 8% 7%

Psychiatric Disorders

Depression 4% 7%

Insomnia 4% 5%

Abnormal dreams 4% 3%

Skin and Subcutaneous Tissue Disorders

5% 4% Rash

Patients who received treatment up to 144 weeks in Study 934 reported adverse events similar in nature and severity to those reported in the first 48 weeks.

Through 48 weeks, 7 patients in the EMTRIVA + VIREAD group and 5 patients in the lamivudine/zidovudine group experienced a new CDC Class C event (10 and 6 patients, respectively, through 144 weeks). Renal safety assessed by laboratory abnormalities was similar in the two groups and no patient discontinued study drug due to renal events. At Week 48 and 144, total limb fat (as measured by dual-energy x-ray absorptiometry) was significantly less in a subgroup of patients in the lamivudine/zidovudine group compared to the tenofovir/emtricitabine subgroup (see Table 7).

Table 7. Study 934: Total Limb Fat at Week 48 and 144 (Dual-Energy

X-Ray Absorptiometry)

Week 48¹

VIREAD + FTC + EFV AZT/3TC +EFV

N=51 N=49

Total Limb Fat (kg)

(Mean ± S.D.) 8.9 ± 5.4 6.9 ± 3.9

Week 144² N=145 N=124

Total Limb Fat (kg)

(Mean ± S.D.) 9.2 ± 5.4 6.5 ± 4.3

1 P = 0.03 for the comparison between arms

2 P < 0.001 for the comparison between arms

Laboratory Abnormalities: Laboratory Abnormalities observed in this study were generally consistent with those seen in other studies (Table 8).

Table 8. Grade 3/4 Laboratory Abnormalities Reported in ≥ 1% in Any

Treatment Group in Study 934 (0-48 weeks)

EMTRIVA+VIREAD+EFV

N=257

AZT/3TC+EFV

N=254

Any ≥ Grade 3 Laboratory Abnormality 25% 22%

Fasting Cholesterol (>240 mg/dL) 15% 17%

Creatine Kinase 7% 6%

(M: >990 U/L)

(F: >845 U/L)

Serum Amylase (>175U/L) 7% 3%

Alkaline Phosphatase (>550 U/L) 1% 0%

AST 3% 2%

(M: >180 U/L)

(F: >170 U/L)

ALT 2% 2%

(M: >215 U/L)

(F: >170 U/L)

Hemoglobin (<8.0 mg/dL) 0% 3%

Hyperglycemia (>250 mg/dl) 1% 1%

Hematuria (>75 RBC/HPF) 2% 2%

Neutrophil (>750/mm3) 3% 4%

Fasting Triglycerides (>750mg/dL) 4% 2%

Laboratory abnormalities in patients who received treatment up to 144 weeks in Study 934 were consistent with those observed in the first 48 weeks of treatment.

Adolescent Patients with HIV-1 Infection

Assessment of adverse reactions is based on one randomized study (Study 321) in 87 HIV-1 infected adolescent patients (12 to <18 years of age) who received treatment with VIREAD (N=45) or placebo (N=42) in combination with other antiretroviral agents for 48 weeks. The adverse reactions observed in adolescent patients who received treatment with VIREAD were consistent with those observed in clinical studies in adults.

Chronic Hepatitis B

Adult Patients

Patients with chronic hepatitis B and compensated liver function received double-blind treatment with VIREAD (N=426) or HEPSERA (N=215) for 48 weeks in studies 0102 (HBeAg-) and 0103 (HBeAg+).

The most common adverse events in TDF-treated patients (incidence ≥5%) identified during the 48-week double blind period of these studies, at any severity and regardless of causality, are presented in Table 9.

Table 9. Treatment-Emergent Adverse Events^a (≥5% in TDF-treated patients) in Pooled Studies GS-US-174-0102 and GS-US-174-0103 (0-48 weeks)

a regardless of causality and severity

The adverse reactions observed with continued treatment for 288 weeks in Studies 0102 and 0103 were consistent with the safety profile of VIREAD.

Adverse events observed in a double-blind, randomized, controlled study (Study 0106) in which 105 patients previously treated with HEPSERA were treated with TDF for 48 weeks were similar in nature to those observed in Studies 0102 and 0103.

No new adverse events causally associated with TDF were identified from a double-blind active controlled study (Study 0108) in which patients with decompensated liver disease

received treatment containing TDF (N=90) for up to 48 weeks. This study was not large enough to detect rare or unexpected adverse events in this patient population. In this study, 7 of 90 patients (8%) receiving a TDF-containing regimen, including 4 of 45 patients (9%) receiving VIREAD, experienced a confirmed increase in serum creatinine of ≥0.5 mg/dL or confirmed decrease in serum phosphorus of <2 mg/dL through Week 48 (see CLINICAL TRIALS for additional safety information regarding VIREAD).

No new adverse reactions to TDF were identified from a randomized, double-blind study (Study 0121) in which lamivudine-resistant patients received treatment containing TDF (N=280) for 96 weeks.

Laboratory Abnormalities: In Studies 0102 and 0103, the most frequently occurring Grade 3 or 4 laboratory abnormality during the 48-week double-blind period in the VIREAD treatment group was ALT increased. All patients with treatment-emergent Grade 3 or 4 ALT increases had elevated ALT at baseline. A summary of Grade 3 and 4 laboratory abnormalities is provided in Table 10.

Table 10. Grade 3/4 Laboratory Abnormalities Reported in ≥ 1% in Any

Treatment Group in Pooled Studies GS-US-174-0102 and GS-US-174-0103 (0–48 weeks)

VIREAD N=426

HEPSERA N=215

Any ≥ Grade 3 Laboratory Abnormality 19% 13%

ALT (>5.00 x ULN) 10% 6%

AST (>5.00 x ULN) 4% 4%

Serum Amylase (>2.0 x ULN) 4% 1%

Urine Glucose (≥3+) 3% 1%

Creatine Kinase (≥10.0 x ULN) 2% 3%

Hyperglycemia (>250 mg/dl) 1% 2%

Grade 3/4 laboratory abnormalities were similar in nature and frequency in patients continuing treatment for up to 288 weeks in these studies. Overall, the following Grade 3–4 laboratory abnormalities were reported in ≥1% of subjects during open-label VIREAD treatment (Weeks 48−288 of Studies 0102 and 0103): urine glucose (5%), AST (4%), prothrombin time (4%), ALT (3%), serum amylase (3%), creatine kinase (3%), serum lipase (2%), and hyperglycemia (2%).

Post Market Adverse Drug Reactions

The following adverse reactions have been identified during post-approval use of VIREAD. Because these events have been reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been considered possible adverse reactions due to a combination of their seriousness, frequency of reporting or potential causal relationship with VIREAD.

Immune system disorders: Allergic reaction (including angioedema)

Metabolism and nutrition disorders: Lactic acidosis, hypokalemia, hypophosphatemia

Respiratory, thoracic and mediastinal

disorders:

Dyspnea

Gastrointestinal disorders: Pancreatitis, increased amylase, abdominal pain

Blood and lymphatic system: Thrombocytopenia

Hepatobiliary disorders: Hepatic steatosis, hepatitis, increased liver enzymes (most commonly AST, ALT, GGT)

Skin and Subcutaneous Tissue Disorders: Rash

Musculoskeletal and Connective Tissue

Disorders:

Rhabdomyolysis, osteomalacia (manifested as bone pain and infrequently contributing to fractures), muscular weakness, myopathy

Renal and urinary disorders: Acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis (including acute cases), nephrogenic diabetes insipidus, renal insufficiency, increased creatinine, proteinuria, polyuria

General disorders and Administration Site

Conditions

Asthenia

The following adverse reactions, listed under the body system headings above, sometimes appeared to be concurrent with proximal renal tubulopathy: rhabdomyolysis, osteomalacia

(manifested as bone pain and infrequently contributing to fractures), hypokalemia, muscular weakness, myopathy, hypophosphatemia.

There have been three post marketing reports of acute renal failure in patients on concomitant NSAIDS therapy where a relationship to VIREAD could not be excluded. These events mostly occurred in medically complex patients, where underlying disease processes confound interpretation.

In HIV-infected patients with severe immune deficiency at the time of initiation of antiretroviral therapy an inflammatory reaction to infectious pathogens (active or inactive) may arise (see WARNINGS and PRECAUTIONS).

In HBV infected patients, clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of HBV therapy (see WARNINGS AND PRECAUTIONS, Exacerbations of Hepatitis after Discontinuation of Treatment).

DRUG INTERACTIONS

Drug-Drug Interactions

At concentrations substantially higher (~300-fold) than those observed in vivo, tenofovir did not inhibit in vitro drug metabolism mediated by any of the following human CYP450 isoforms: CYP3A4, CYP2D6, CYP2C9 or CYP2E1. However, a small (6%) but statistically significant reduction in metabolism of CYP1A substrate was observed. Based on the results of in vitro experiments and the known elimination pathway of tenofovir, the potential for CYP450 mediated interactions involving tenofovir with other medicinal products is low (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics).

Established and Other Potentially Significant Drug Interactions

The drug interactions described are based on studies conducted with VIREAD as an individual agent and/or in combination, or are potential drug interactions that may occur with VIREAD.

Table 11. Established and Other Potentially Significant^a Drug Interactions

Concomitant Drug

Class: Drug Name

Effect on

Concentration^b Clinical Comment

Antiretroviral Agents:

Didanosine ↑ didanosine Pharmacokinetic studies have shown that coadministration of didanosine and TDF results in 40–60% increase in C_max and AUC of didanosine (see Table 12). The mechanism of this interaction is unknown. Increases in didanosine concentrations of this magnitude could potentiate didanosine-associated adverse events, including pancreatitis, lactic acidosis, and neuropathy. In addition, suppression of CD4 counts has been observed in patients receiving TDF with didanosine at a dose of 400 mg daily.

A reduced dose of Videx EC^® (ddI-EC) is recommended when

Concomitant Drug

Class: Drug Name

Effect on

Concentration^b Clinical Comment

coadministered with VIREAD. When coadministered with VIREAD, the Videx EC^® Product Monograph recommends a reduced dose of 250 mg ddI-EC for HIV-infected adults with body weight ≥60 kg and creatinine clearance ≥60 mL/min. For adult patients with body weight <60 kg, and creatinine clearance ≥60 mL/min, the recommended dose of ddI-EC is 200 mg. Data are not available to recommend a dose adjustment for patients with creatinine clearance <60 mL/min or for the buffered tablet formulation of didanosine (Videx^®).

Caution should be used when coadministering reduced-dose didanosine, tenofovir, and an NNRTI in treatment-naïve patients with high viral loads at baseline since such use has been associated with reports of a high rate of virologic failure and emergence of resistance at an early stage. All patients receiving TDF and didanosine concomitantly should be closely monitored for didanosine-related adverse events and clinical response.

Atazanavir/ritonavir

Darunavir/ritonavir

Lopinavir/ritonavir

↑ tenofovir Atazanavir/ritonavir, darunavir/ritonavir and lopinavir/ritonavir have been shown to increase tenofovir concentrations (see Table 13). The mechanism of this interaction is unknown. Higher tenofovir concentrations could potentiate TDF-associated adverse events, including renal disorders. Patients should be monitored for TDF-associated adverse events when receiving

atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir in combination with TDF.

Atazanavir ↓ atazanavir Tenofovir decreases atazanavir concentrations (see Table 14).

Although safety and efficacy data are limited, it is recommended that atazanavir, without ritonavir, should not be coadministered with TDF. The recommended regimen is atazanavir 300 mg given with ritonavir 100 mg when used in combination with TDF 300 mg (all as a single daily dose with food).

Hepatitis C Virus Antiviral Agents:

Ledipasvir/sofosbuvir

Sofosbuvir/velpatasvir

Sofosbuvir/velpatasvir/

voxilaprevir

↑ tenofovir Coadministration of TDF and HARVONI, EPCLUSA

(sofosbuvir/velpatasvir), or VOSEVI

(sofosbuvir/velpatasvir/voxilaprevir) has been shown to increase tenofovir exposure (see Table 13). Patients receiving a regimen containing TDF concomitantly with HARVONI, EPCLUSA, or VOSEVI should be monitored for adverse reactions associated with TDF.

a This table is not all inclusive.

b ↑ = increase, ↓ = decrease

Drugs Affecting Renal Function

Tenofovir is primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion. Coadministration of VIREAD with drugs that are eliminated by active tubular secretion may increase serum concentrations of either tenofovir or the coadministered drug, due to competition for this elimination pathway. Some examples include, but are not limited to cidofovir, acyclovir, valacyclovir, ganciclovir, and

valganciclovir. Drugs that decrease renal function may also increase serum concentrations of tenofovir.

VIREAD should not be administered in combination with HEPSERA (adefovir dipivoxil) (see WARNINGS AND PRECAUTIONS, General).

Drugs without Clinically Significant Interactions with VIREAD

There were no clinically significant drug interactions observed when TDF was coadministered with abacavir, efavirenz, emtricitabine, entecavir, indinavir, lamivudine, methadone, nelfinavir, oral contraceptives, ribavirin, rifampicin, saquinavir/ritonavir, sofosbuvir and tacrolimus (see Table 13 and Table 14).

Assessment of Drug Interactions

Drug-drug interaction studies were conducted with VIREAD as an individual agent and/or in combination with emtricitabine.

The effects of didanosine in the presence of VIREAD are shown in Table 12.

The effects of coadministered drugs on the exposure of VIREAD are shown in Table 13. The effects of VIREAD on the exposure of coadministered drugs are shown in Table 14.

Table 12. Drug Interactions: Pharmacokinetic Parameters for Didanosine in the Presence of VIREAD

Didanosine¹ Dose (mg)/

Method of

Administration²

% Difference (90% CI) vs. Didanosine 400 mg Alone, Fasted³

AUC

Buffered tablets

400 once daily⁴ × 7 days

↑ 43

(↑ 30 to ↑ 57)

Enteric coated capsules

400 once, fasted

↑ 48

(↑ 31 to ↑ 67)

400 once, with food

↑ 60

(↑ 44 to ↑ 79)

250 once, fasted

0

(↓ 11 to ↑ 12)

250 once, fasted

↑ 14

(0 to ↑ 31)

Didanosine¹ Dose (mg)/ Method of

Administration²

% Difference (90% CI) vs. Didanosine 400 mg Alone, Fasted³

AUC

250 once, with food

↓ 11

(↓ 23 to ↑ 2)

1 See PRECAUTIONS regarding use of didanosine with VIREAD.

2 Administration with food was with a light meal (~373 kcal, 20% fat).

3 Increase = ↑; Decrease = ↓

4 Includes 4 subjects weighing < 60 kg receiving ddI 250 mg.

Table 13. Drug Interactions: Changes in Pharmacokinetic Parameters for

Tenofovir¹ in the Presence of the Coadministered Drug

Coadministered

Drug

% Change of Tenofovir Pharmacokinetic Parameters²

(90% CI)

Cmin

Abacavir

NC

Atazanavir sulfate³

↑ 22

(↑ 15 to ↑ 30)

Atazanavir/ Ritonavir³

↑ 29

(↑ 21 to ↑ 36)

Darunavir/Ritonavir⁴

↑ 37

(↑ 19 to ↑ 57)

Didanosine (enteric-coated)

NC

Didanosine (buffered)⁴

↓ 22

(↓ 36 to ↓ 7)

Efavirenz

↑ 2

(↓ 9 to ↑ 12)

Emtricitabine

↑ 2

(↓ 8 to ↑ 13)

Entecavir

NA

Indinavir

↑ 8

(↓ 7 to ↑ 22)

Lamivudine

↓ 8

(↓ 33 to ↑ 18)

Coadministered Drug

% Change of Tenofovir Pharmacokinetic Parameters²

(90% CI)

Cmin

Ledipasvir/ Sofosbuvir^,6,7

↑ 47

(↑ 38 to ↑ 57)

Ledipasvir/ Sofosbuvir^6,8

↑ 59

(↑ 49 to ↑ 70)

Ledipasvir/ Sofosbuvir⁹

↑ 163

(↑ 132 to↑197)

Ledipasvir/ Sofosbuvir¹⁰

↑ 91

(↑ 74 to ↑ 110)

Ledipasvir/ Sofosbuvir¹¹

↑ 115

(↑ 105 to ↑ 126)

Lopinavir/ Ritonavir

↑ 28

(↑ 7 to ↑ 49)

Nelfinavir

↑ 9

(↑ 2 to ↑ 17)

Saquinavir/Ritonavi r

↑ 23

(↑ 16 to ↑ 30)

Sofosbuvir¹²

↓ 1

(↓ 9 to ↑ 7)

Sofosbuvir/ Velpatasvir¹³

↑ 39

(↑ 31 to ↑ 48)

Sofosbuvir/ Velpatasvir¹⁴

↑ 52

(↑ 45 to ↑ 59)

Sofosbuvir/ Velpatasvir¹⁵

↑ 121

(↑ 100 to ↑ 143)

Sofosbuvir/ Velpatasvir¹⁶

↑ 84

(↑ 76 to ↑ 92)

Sofosbuvir/ Velpatasvir¹⁷

↑ 45

(↑ 39 to ↑ 51)

Sofosbuvir/ Velpatasvir¹⁸

↑ 70

(↑ 61 to ↑ 79)

Sofosbuvir/ Velpatasvir/ Voxilaprevir¹⁹

↑ 47

(↑ 38 to ↑ 56)

Tacrolimus

↑ 11

(↑ 4 to ↑ 18)

1. 1. Patients received VIREAD 300 mg once daily.
2. 2. Increase = ↑; Decrease = ↓; NA = Not Available; NC = Not Calculated.
3. 3. Reyataz^® Prescribing Information (Bristol-Myers Squibb).
4. 4. Includes 4 subjects weighing < 60 kg receiving ddI 250 mg.
5. 5. Weight <60kg: 250 mg, ≥60 kg more: 400 mg.
6. 6. Data generated from simultaneous dosing with HARVONI. Staggered administration (12 hours apart) provides similar results.
7. 7. Comparison based on exposures when administered as atazanavir/ritonavir + emtricitabine/TDF coadministered with HARVONI (ledipasvir/sofosbuvir).
8. 8. Comparison based on exposures when administered as darunavir/ritonavir + emtricitabine/TDF coadministered with HARVONI.
9. 9. Study conducted with ATRIPLA (efavirenz/emtricitabine/TDF) coadministered with HARVONI.
10. 10. Study conducted with COMPLERA (emtricitabine/rilpivirine/TDF) coadministered with HARVONI.
11. 11. Study conducted with TRUVADA (emtricitabine/TDF) + dolutegravir coadministered with HARVONI.
12. 12. Study conducted with ATRIPLA coadministered with SOVALDI^® (sofosbuvir).
13. 13. Comparison based on exposures when administered as atazanavir/ritonavir + emtricitabine/TDF coadministered with EPCLUSA.
14. 14. Comparison based on exposures when administered as darunavir/ritonavir + emtricitabine/TDF coadministered with EPCLUSA.
15. 15. Study conducted with ATRIPLA (efavirenz/emtricitabine/TDF) coadministered with EPCLUSA.
16. 16. Study conducted with COMPLERA (emtricitabine/rilpivirine/TDF) coadministered with EPCLUSA.
17. 17. Study conducted with STRIBILD (elvitegravir/cobicistat/emtricitabine/TDF) coadministered with EPCLUSA.
18. 18. Administered as raltegravir + TRUVADA coadministered with EPCLUSA.
19. 19. Comparison based on exposures when administered as darunavir/ritonavir + emtricitabine/TDF.
20. 20. Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV-infected patients.

Table 14. Drug Interactions: Changes in Pharmacokinetic Parameters for

Coadministered Drug in the Presence of VIREAD

Coadministered

Drug

% Change of Coadministered Drug Pharmacokinetic

Parameters¹ (90% CI)

Cmin

Abacavir

NC

Atazanavir

↓ 40

(↓ 48 to ↓ 32)

Atazanavir²

↓ 23³

(↓ 46 to ↑ 10)

Efavirenz

↓ 7

(↓ 13 to ↓ 1)

Emtricitabine

↑ 20

(↑ 12 to ↑ 29)

Entecavir

NA

Indinavir

↑ 43

(↓ 45 to ↑ 130)

Coadministered Drug

% Change of Coadministered Drug Pharmacokinetic

Parameters¹ (90% CI)

Cmin

Lamivudine

↑ 17

(↑ 3 to ↑ 32)

Ledipasvir

↑ 118

(↑ 91 to ↑ 150)

Sofosbuvir

NC

GS-331007⁸

↑ 42

(↑ 34 to ↑ 49)

Ledipasvir

↑ 17

(↑ 4 to ↑ 31)

Sofosbuvir

NC

GS-331007⁸

↑ 26

(↑ 20 to ↑ 32)

Ledipasvir

↓ 34

(↓ 43 to ↓ 24)

Sofosbuvir

NC

GS-331007⁸

↑ 7

(↑ 2 to ↑ 13)

Ledipasvir

↑16

(↑ 8 to ↑ 25)

Sofosbuvir

NC

GS-331007⁸

↑18

(↑ 13 to ↑ 23)

Sofosbuvir

NC

GS-331007⁸

↑ 42

(↑ 37 to ↑ 49)

Velpatasvir

↑ 301

(↑ 257 to ↑ 350)

Sofosbuvir

NC

GS-331007⁸

↑ 13

(↑ 6 to ↑ 19)

Coadministered Drug

% Change of Coadministered Drug Pharmacokinetic

Parameters¹ (90% CI)

Cmin

Velpatasvir

↑ 1

(↓ 13 to ↑ 18)

Sofosbuvir

NC

GS-331007⁸

↑ 1

(↓ 5 to ↑ 7)

Velpatasvir

↓ 57

(↓ 64 to ↓ 48)

Sofosbuvir

NC

GS-331007⁸

↑ 12

(↑ 7 to ↑ 17)

Velpatasvir

↑ 2

(↓ 9 to ↑ 15)

Sofosbuvir

NC

GS-331007⁸

↑ 45

(↑ 38 to ↑ 52)

Velpatasvir

↑ 37

(↑ 22 to ↑ 54)

Sofosbuvir

NC

GS-331007⁸

↑ 8

(↑ 4 to ↑ 13)

Velpatasvir

↓ 3

(↓ 13 to ↑ 7)

Sofosbuvir

ΝΑ

GS-331007

ΝΑ

Velpatasvir

↑ 16

(↑ 7 to ↑ 26)²²

Voxilaprevir

↑ 300

(↑ 244 to ↑ 365)²²

Coadministered Drug

% Change of Coadministered Drug Pharmacokinetic

Parameters¹ (90% CI)

Cmin

Lopinavir

↓ 11

(↓ 22 to ↑ 1)

Ritonavir

↓ 15

(↓ 32 to ↑ 2)

Methadone⁴

↑ 6

(↓ 3 to ↑ 15)

Nelfinavir

↑ 1

(↓ 15 to ↑ 19)

M8 metabolite

↓2

(↓ 16 to ↑ 15)

Norgestimate ⁶

↓ 4

(↓ 8 to ↑ 1)

Ethinyl Estradiol

↓ 2

(↓ 9 to ↑ 6)

Ribavirin

NC

Saquinavir

↑ 47⁷

(↑ 23 to ↑ 76)

Ritonavir

↑ 23

(↑ 3 to ↑ 46)

Sofosbuvir

NC

GS-331007⁸

NC

Tacrolimus

↑ 10

(↑ 2 to ↑ 17)

1. 1. Increase = ↑; Decrease = ↓; NA = Not Available; NC = Not Calculated.
2. 2. Reyataz Prescribing Information (Bristol-Myers Squibb).
3. 3. In HIV-infected patients, addition of TDF to atazanavir 300 mg plus ritonavir 100 mg, resulted in AUC and C_min values of atazanavir that were 2.3 and 4-fold higher than the respective values observed for atazanavir 400 mg when given alone.
4. 4. R-(active), S-and total methadone exposures were equivalent when dosed alone or with VIREAD
5. 5. Individual subjects were maintained on their stable methadone dose. No pharmacodynamic alterations (opiate toxicity or withdrawal signs or symptoms) were reported.
6. 6. Ethinyl estradiol and 17-deacetyl norgestimate (pharmacologically active metabolite) exposures were equivalent when dosed alone or with VIREAD.
7. 7. Increase in AUC and C_min are not expected to be clinically relevant; hence no dose adjustments are required when TDF and ritonavir-boosted saquinavir are coadministered.
8. 8. The predominant circulating nucleoside metabolite of sofosbuvir.
9. 9. Data generated from simultaneous dosing with HARVONI. Staggered administration (12 hours apart) provides similar results.
10. 10. Comparison based on exposures when administered as atazanavir/ritonavir + emtricitabine/TDF coadministered with HARVONI (ledipasvir/sofosbuvir).
11. 11. Comparison based on exposures when administered as darunavir/ritonavir + emtricitabine/TDF coadministered with HARVONI.
12. 12. Study conducted with ATRIPLA (efavirenz/emtricitabine/TDF) coadministered with HARVONI.
13. 13. Study conducted with COMPLERA (emtricitabine/rilpivirine/TDF) coadministered with HARVONI.
14. 14. Comparison based on exposures when administered as atazanavir/ritonavir + emtricitabine/TDF coadministered with EPCLUSA (sofosbuvir/velpatasvir).
15. 15. Comparison based on exposures when administered as darunavir/ritonavir + emtricitabine/TDF coadministered with EPCLUSA.
16. 16. Study conducted with ATRIPLA (efavirenz/emtricitabine/TDF) coadministered with EPCLUSA.
17. 17. Study conducted with COMPLERA (emtricitabine/rilpivirine/tenofovir DF) coadministered with EPCLUSA.
18. 18. Study conducted with STRIBILD (elvitegravir/cobicistat/emtricitabine/TDF) coadministered with EPCLUSA.
19. 19. Comparison based on exposures when administered as raltegravir + TRUVADA coadministered with EPCLUSA.
20. 20. Study conducted with ATRIPLA coadministered with SOVALDI (sofosbuvir).
21. 21. Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV-infected patients.
22. 22. Comparison based on exposures when administered as darunavir/ritonavir + emtricitabine/TDF.

Drug-Food Interactions

VIREAD can be taken with or without food. Administration of VIREAD following a high-fat meal (~700 to 1000 kcal containing 40–50% fat) increases the oral bioavailability, with an increase in tenofovir AUC_0-∞ of approximately 40% and an increase in C_max of approximately 14% (see ACTION AND CLINICAL PHARMACOLOGY, Effect of Food on Absorption).

Drug-Herb Interactions

Interactions of VIREAD with herbs have not been established.

Drug-Laboratory Interactions

Interactions of VIREAD with laboratory tests have not been established.

DOSAGE AND ADMINISTRATION

Adults

For the treatment of HIV or chronic hepatitis B: The dose of VIREAD (TDF) is 300 mg once daily taken orally without regard to food.

In the treatment of chronic hepatitis B, the optimal duration of treatment is unknown. VIREAD may be discontinued if there is HBsAg loss or HBsAg seroconversion.

Adolescent Patients with HIV-1 Infection (12 Years of Age and Over)

Body weight ≥35 kg (≥77 lb): Take one 300 mg VIREAD tablet once daily orally, without regard to food.

Dose Adjustment for Renal Impairment

Significantly increased drug exposures occurred when VIREAD was administered to patients with moderate to severe renal impairment (see ACTION AND CLINICAL PHARMACOLOGY, Renal Insufficiency). Therefore, the dosing interval of VIREAD should be adjusted in patients with baseline creatinine clearance <50 mL/min using the recommendations in Table 15. These dosing interval recommendations are based on modeling of single-dose pharmacokinetic data in non-HIV and non-HBV infected subjects with varying degrees of renal impairment, including end-stage renal disease requiring hemodialysis. The safety and efficacy of these dosing interval adjustment recommendations have not been clinically evaluated in moderate to severe renal impairment, therefore, clinical response to treatment and renal function should be closely monitored in these patients.

No dose adjustment of VIREAD tablets (300 mg) is necessary in patients with mild renal impairment (creatinine clearance 50−80 mL/min). Routine monitoring of calculated creatinine clearance, serum phosphorus, urine glucose and urine protein should be performed in patients with mild renal impairment (see WARNINGS and PRECAUTIONS).

Table 15. Dosage Recommendations for Patients with Altered Creatinine

Clearance

Creatinine Clearance

(mL/min)¹ Hemodialysis Patients

Recommended 300 mg Dosing Interval

Every 7 days or after a total of approximately 12 hours of dialysis²

1 Calculated using ideal (lean) body weight.

2 Generally once weekly assuming three hemodialysis sessions a week of approximately 4 hours duration. VIREAD should be administered following completion of dialysis.

The pharmacokinetics of tenofovir have not been evaluated in non-hemodialysis patients with creatinine clearance <10 mL/min; therefore, no dosing recommendation is available for these patients.

No data are available to make dose recommendations in adolescent patients with renal impairment.

Missed Dose

If a patient misses a dose at the regularly scheduled time, but then remembers it that same day, the patient should take the missed dose immediately. The next dose should be taken at the regularly scheduled time the following day. The patient should not take two doses of VIREAD at once to make up for missing a dose.

OVERDOSAGE

For management of a suspected drug overdose, please contact your Regional Poison Control Centre.

Limited clinical experience at doses higher than the therapeutic dose of VIREAD 300 mg is available. In Study 901 TDF 600 mg was administered to 8 patients orally for 28 days. No severe adverse reactions were reported. The effects of higher doses are not known.

If overdose occurs the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary. Administration of activated charcoal may also be used to aid in removal of unabsorbed drug.

Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of VIREAD, a four-hour hemodialysis session removed approximately 10% of the administered tenofovir dose.

ACTION AND CLINICAL PHARMACOLOGY

VIREAD is an acyclic nucleotide diester analog of adenosine monophosphate. TDF requires initial diester hydrolysis (by non-specific esterases in blood and tissues) for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate, an obligate chain terminator. Tenofovir diphosphate inhibits the activity of HIV reverse transcriptase and HBV polymerase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination.

Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.

VIREAD is a water soluble diester prodrug of the active ingredient tenofovir. Following oral administration of a single dose of VIREAD 300 mg to HIV-infected patients in the fasted state, maximum serum concentrations (C_max) of tenofovir are achieved in 1.0 ± 0.4 hours. The oral bioavailability of tenofovir from VIREAD in fasted patients is approximately 25%. Administration of VIREAD following a high-fat meal increases the oral bioavailability, with an increase in tenofovir AUC_∞ of approximately 40% and an increase in C_max of approximately 14% (see DOSAGE AND ADMINISTRATION).

Tenofovir is eliminated by a combination of glomerular filtration and active tubular secretion. There may be competition with other compounds that are also renally eliminated.

Pharmacodynamics

Activity in HIV-1

The in vitro antiviral activity of tenofovir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, primary monocyte/macrophage cells and peripheral blood lymphocytes. The IC₅₀ values for tenofovir were in the range of 0.04−8.5 μM. In drug combination studies of tenofovir with integrase strand transfer inhibitors (elvitegravir or raltegravir), nucleoside reverse transcriptase inhibitors (abacavir, didanosine, emtricitabine, lamivudine, stavudine, zalcitabine, or zidovudine), non-nucleoside reverse transcriptase inhibitors (delavirdine, efavirenz, nevirapine or rilpivirine), and protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, or saquinavir), additive to synergistic effects were observed. Most of these drug combinations have not been studied in humans. Tenofovir displayed antiviral activity in vitro against HIV-1 clades A, B, C, D, E, F, G, and O (IC₅₀ values ranged from 0.5−2.2 μM).

The antiviral effects of TDF monotherapy in reducing HIV-1 viral load and the relationship with dose were assessed in clinical phase 1 studies in treatment-naive and treatment-experienced HIV-infected patients. Doses of TDF ranging from 75 mg to 600 mg once daily resulted in statistically significant decreases in plasma HIV-1 RNA levels compared with placebo. In a mixed population of treatment-naive and treatment-experienced patients who received 28 days of repeat daily dosing with TDF 300 mg QD (Study GS-97-901) the median decrease in plasma log₁₀ HIV-1 RNA level was 1.22 log₁₀ copies/mL.

Activity in HBV

The in vitro antiviral activity of tenofovir against HBV was assessed in the HepG2 2.2.15 cell line. The EC₅₀ values for tenofovir were in the range of 0.14 to 1.5 μM, with CC₅₀ (50% cytotoxicity concentration) values >100 μM. Tenofovir diphosphate inhibits recombinant HBV polymerase with a Ki (inhibition constant) of 0.18 μM. In in vitro drug combination studies of tenofovir with nucleoside anti-HBV reverse transcriptase inhibitors lamivudine, telbivudine, and entecavir, additive anti-HBV activity was observed. Additive to slightly synergistic effects were observed with the combination of tenofovir and emtricitabine.

Pharmacokinetics

Pharmacokinetics of intravenous tenofovir were evaluated in Study GS-96-701 (N=16). Following intravenous administration of tenofovir 1.0 and 3.0 mg/kg, pharmacokinetics were dose-proportional with the exception of the estimated terminal half-life (5.3 and 7.8 hours, respectively). The pharmacokinetics of tenofovir were not affected by repeated dosing in the 1.0 mg/kg/day group, with the exception of half-life (5.3 on Day 1 vs. 7.7 on Day 14) and volume of distribution (763 vs. 1320 mL/kg). At the 3.0 mg/kg/day, there was an approximate 27% decrease in serum clearance of tenofovir following 7 days of once daily administration; renal clearance and estimated terminal half-life were also significantly different.

The pharmacokinetics of tenofovir following administration of TDF were evaluated in the fasted state in Study GS-97-901 (HIV-infected patients) and Study GS-00-914 (healthy volunteers). The pharmacokinetics in HIV-infected patients and healthy volunteers were similar. The estimated terminal half-life in HIV-infected patients measured over 24 hours was ~12–13 hr. The terminal elimination half-life in healthy subjects assessed over 48 hours was ~17 hours. There were no significant differences in the dose-normalized steady-state pharmacokinetics of tenofovir over the dose range of 75 to 600 mg. Tenofovir exposure following 8 and 28 days was slightly higher than those observed following the first dose.

Absorption

VIREAD is a water soluble diester prodrug of the active ingredient tenofovir. The oral bioavailability of tenofovir from VIREAD in fasted patients is approximately 25%. Following oral administration of a single dose of VIREAD 300 mg to HIV-infected patients in the fasted state, maximum serum concentrations (C_max) are achieved in 1.0 ± 0.4 hours. C_max and AUC values are 296 ± 90 ng/mL and 2287 ± 685 ng•hr/mL, respectively.

Distribution

In vitro binding of tenofovir to human plasma or serum proteins is less than 0.7 and 7.2%, respectively, over the tenofovir concentration range 0.01–25 μg/mL. The volume of distribution at steady-state is 1.3±0.6 L/kg and 1.2±0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.

Metabolism

In vitro studies indicate that neither tenofovir disoproxil nor tenofovir are substrates of CYP450 enzymes.

Following IV administration of tenofovir, approximately 70–80% of the dose is recovered in the urine as unchanged tenofovir within 72 hours of dosing. After multiple oral doses of VIREAD 300 mg once daily (under fed conditions), 32±10% of the administered dose is recovered in urine over 24 hours.

Excretion

Tenofovir is eliminated by a combination of glomerular filtration and active tubular secretion. There may be competition for elimination with other compounds that are also renally eliminated.

Effects of Food on Oral Absorption

Administration of VIREAD following a high-fat meal (~700 to 1000 kcal containing 40–50% fat) increases the oral bioavailability, with an increase in tenofovir AUC_0-∞ of approximately 40% and an increase in C_max of approximately 14%. Food delays the time to tenofovir C_max by approximately 1 hour. C_max and AUC of tenofovir are 326±119 ng/mL and

3324±1370 ng•hr/mL following multiple doses of VIREAD 300 mg once daily in the fed state, when meal content was not controlled.

Special Populations and Conditions

Pediatric Patients

Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1 infected adolescent patients (12 to <18 years). All pediatric patients were receiving VIREAD with a ritonavir-boosted protease inhibitor. Mean (± SD) C_max and AUC_tau are 0.38±0.13 μg/mL and 3.39±1.22 μg•hr/mL, respectively. Tenofovir exposure achieved in adolescent patients receiving oral daily doses of VIREAD 300 mg was similar to exposures achieved in adults receiving once-daily doses of VIREAD 300 mg.

Geriatrics

Pharmacokinetic studies have not been performed in the elderly.

Race

There were insufficient numbers from racial and ethnic groups other than Caucasian to adequately determine potential pharmacokinetic differences among these populations.

Gender

Limited data on the pharmacokinetics of tenofovir in women indicate no major gender effect.

Hepatic Insufficiency

The pharmacokinetics of tenofovir following a 300 mg single dose of VIREAD have been studied in 8 non-HIV, non-HBV infected subjects with moderate hepatic impairment and 8 non-HIV infected subjects with severe hepatic impairment. There were no substantial alterations in tenofovir pharmacokinetics in subjects with hepatic impairment compared with unimpaired subjects. No change in VIREAD dosing is required in patients with hepatic impairment.

Renal Insufficiency

The pharmacokinetics of tenofovir are altered in subjects with renal impairment (see WARNINGS, Nephrotoxicity). In non-HIV, non-HBV infected subjects with creatinine clearance <50 mL/min or with end-stage renal disease (ESRD) requiring dialysis, C_max, and AUC_0-∞ of tenofovir were increased (Table 16). It is recommended that the dosing interval for VIREAD be modified in patients with creatinine clearance <50 mL/min or in patients with ESRD who require dialysis (see DOSAGE AND ADMINISTRATION).

Table 16. Pharmacokinetic Parameters (Mean ± SD) of Tenofovir* in

Patients with varying Degrees of Renal Function

Baseline Creatinine

Clearance (mL/min)

12–29 (N=11)

C_max (ng/mL)

601.6±185.3

AUC_∞ (ng•hr/mL)

15984.7±7223.0

CL/F (mL/min)

177.0±97.1

CL_renal (mL/min)

43.0±31.2

* 300 mg, single dose of VIREAD

Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of VIREAD, a four-hour hemodialysis session removed approximately 10% of the administered tenofovir dose.

STORAGE AND STABILITY

Store at 25 °C (77 °F), excursions permitted to 15–30 °C (59–86 °F).

SPECIAL HANDLING INSTRUCTIONS

There are no special handling instructions.

DOSAGE FORMS, COMPOSITION AND PACKAGING

VIREAD is available as tablets. Each tablet contains 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil, and the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. The tablets are coated with a blue colored film (Opadry II Y-30-10671-A) that is made of FD&C blue #2 aluminum lake, hydroxypropyl methylcellulose 2910, lactose monohydrate, titanium dioxide, and triacetin. The tablets are almond-shaped, light blue, film-coated and debossed with “GILEAD” and “4331” on one side and with “300” on the other side. Available in bottles containing 30 tablets with a desiccant (silica gel canister or sachet) and closed with child-resistant closure.

1. 2. SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Common Name: tenofovir disoproxil fumarate (USAN)

Chemical Name: 9-[(R)-2-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]-methoxy]propyl]adenine fumarate (1:1) Empirical Formula: C₁₉H₃₀N₅O₁₀P • C₄H₄O₄

Molecular Weight: 635.52

Structural Formula:

N

N

N

N

NH₂

O P

CH₃

O

O

O

O

O

O

O

O

O C C

H

CO₂H H

HO₂C

•

Physicochemical

Properties:

Physical Description: Tenofovir disoproxil fumarate is a white to off-white crystalline powder.

Solubility: The solubility of tenofovir disoproxil fumarate is 13.4 mg/mL in water at 25 °C. The partition coefficient (log p) for tenofovir disoproxil is 1.25.

CLINICAL TRIALS

Clinical Efficacy in Patients with HIV

Study Demographics and Trial Design

Treatment-Experienced Adult Patients

Study 907 - VIREAD + Standard Background Therapy (SBT) Compared to Placebo + SBT: Study 907 was a 24-week, double-blind placebo-controlled multicenter study of VIREAD added to a stable background regimen of antiretroviral agents in 550 treatment-experienced patients. After 24 weeks of blinded study treatment, all patients continuing on study were offered open-label VIREAD for an additional 24 weeks. Patients had a mean baseline CD4 cell count of 427 cells/mm³ (range 23–1385), median baseline plasma HIV RNA of 2340 (range 50–75,000) copies/mL, and mean duration of prior HIV treatment was 5.4 years. Mean age of the patients was 42 years, 85% were male and 69% were Caucasian, 17% Black and 12% Hispanic.

Table 17. Study 907: VIREAD + Standard Background Therapy (SBD)

Compared to Placebo + SBD

Study

No.

Gender

GS-99-907

Male: 85% Female:15%

Treatment-Naïve Adult Patients

Study 903 - VIREAD + Lamivudine +Efavirenz Compared to Stavudine + Lamivudine + Efavirenz: Data through 144 weeks are reported for Study 903, a double-blind, active-controlled multicenter study comparing VIREAD (300 mg QD) administered in combination with lamivudine and efavirenz versus stavudine, lamivudine, and efavirenz in 600 antiretroviral-naïve patients. Patients had a mean age of 36 years (range 18–64), 74% were male, 64% were Caucasian and 20% were Black. The mean baseline CD4 cell count was 279 cells/mm³ (range 3–956) and median baseline plasma HIV-1 RNA was 77,600 copies/mL (range 417-5,130,000). Patients were stratified by baseline HIV-1 RNA and CD4 count. Forty-three percent of patients had baseline viral loads > 100,000 copies/mL and 39% had CD4 cell counts < 200 cells/mL.

Table 18. Study 903: VIREAD + Lamivudine + Efavirenz Compared with

Stavudine + Lamivudine + Efavirenz

Study

No.

Gender

GS-99-903

Male:

74%

Female: 26%

1 Stavudine/placebo capsules 20/15 mg BID as need for dose reduction.

Study 934 - VIREAD + Emtricitabine+ Efavirenz Compared with Lamivudine/Zidovudine + Efavirenz: Data through 144 weeks are reported for Study 934, a randomized, open-label, active-controlled multicenter study comparing VIREAD (300 mg QD) + emtricitabine (200 mg QD) administered in combination with efavirenz (600 mg QD) versus lamivudine 150 mg/ zidovudine 300 mg BID administered in combination with efavirenz (600 mg QD) in 511 antiretroviral-naïve patients. From weeks 96 to 144 of the study, patients randomized to VIREAD + emtricitabine received TRUVADA with efavirenz in place of emtricitabine + VIREAD. Patients had a mean age of 38 years (range 18–80), 86% were male, 59% were Caucasian and 23% were Black. The mean baseline CD4 cell count was 245 cells/mm³ (range 2–1191) and median baseline plasma HIV-1 RNA was 5.01 log₁₀ copies/mL (range 3.56–6.54). Patients were stratified by baseline CD4 count (< or ≥200 cells/mm³); 41% had CD4 cell counts < 200 cells/mm³ and 51% of patients had baseline viral loads > 100,000 copies/mL.

Table 19. Study 934: EMTRIVA+ VIREAD + Efavirenz Compared with

Lamivudine/Zidovudine +Efavirenz

Study

Number

Gender

GS-01-93 4

Male: 86% Female:14%

1 From weeks 96 to 144 of the study, patients received TRUVADA with efavirenz in place of emtricitabine + VIREAD

Study Results

Study 907 - VIREAD + Standard Background Therapy (SBT) Compared to Placebo + SBT: Changes from baseline in log₁₀ copies/mL plasma HIV-1 RNA levels through Week 48 are presented in Table 20.

Table 20. Mean Change from Baseline in Plasma HIV-1 RNA (log₁₀ copies/mL): Study 907 (48 weeks)

Study Week

HIV-1 RNA log₁₀ copies/mL

VIREAD

(N=368)

Placebo

(N=182)

Week 12 –0.65 (N=354) –0.08 (N=175)

Week 24 –0.59 (N=346) –0.01 (N=172)

VIREAD

(N=368)

Placebo Crossover to

VIREAD¹

(N=170)

Week 32 –0.55 (N=346) –0.61 (N=167)

Week 40 –0.49 (N=336) –0.61 (N=162)

Week 48 –0.53 (N=327) –0.64 (N=160)

1 For Placebo Crossover to VIREAD, baseline HIV-1 RNA was reset at Week 24.

The percent of patients with HIV-1 RNA <400 copies/mL and outcomes of patients through 48 weeks are summarized in Table 21.

Table 21. Outcomes of Randomized Treatment (Study 907)

Outcomes

24–48 weeks

Placebo Crossover to

VIREAD

(N=170)

HIV-1 RNA

< 400 copies/mL¹

30%

Virologic failure²

64%

Discontinued due to adverse event

5%

Discontinued for other reasons³

1%

1 Patients with HIV-1 RNA <400 copies/mL and no prior study drug discontinuation at Week 24 and 48, respectively. 2 Patients with HIV-1 RNA ≥400 copies/mL efficacy failure or missing HIV–1 RNA at Week 24 and 48, respectively. 3 Includes lost to follow-up, patient withdrawal, noncompliance, protocol violation and other reasons.

At 24 weeks of therapy, there was a higher proportion of patients in the VIREAD arm compared to the placebo arm with HIV-1 RNA <50 copies/mL (22% and 1%, respectively). Mean change in absolute CD4 counts by Week 24 was +12 cells/mm³ for the VIREAD group and –5 cells/mm³ for the placebo group. Mean change in absolute CD4 counts by Week 48 was +4 cells/mm³ for the VIREAD group.

Through Week 24, one patient in the VIREAD group and no patients in the placebo arm experienced a new CDC Class C event.

Study 903 - VIREAD + Lamivudine + Efavirenz Compared to Stavudine + Lamivudine + Efavirenz: Treatment outcomes through 144 weeks are presented in Table 22.

Table 22. Outcomes of Randomized Treatment (Study 903)

Outcomes

At Week 144

Stavudine + 3TC + EFV (N=301)

Responder¹

62%

Virologic failure²

8%

Rebound

7%

Never suppressed

0%

Added an antiretroviral agent

1%

Death

2%

Discontinued due to adverse event

13%

Discontinued for other reasons³

15%

1 Patients achieved and maintained confirmed HIV-1 RNA <400 copies/mL through Week 144. 2 Includes confirmed viral rebound and failure to achieve confirmed <400 copies/mL through Week 144. 3 Includes lost to follow-up, patient’s withdrawal, noncompliance, protocol violation and other reasons.

Achievement of plasma HIV-1 RNA concentrations of less than 400 copies/mL at Week 144 was similar between the two treatment groups for the population stratified at baseline on the basis of HIV-1 RNA concentration (≤ or > 100,000 copies/mL) and CD4 cell count (< or ≥200 cells/mm³). Through 144 weeks of therapy, 62% and 58% of patients in the VIREAD and stavudine arms, respectively achieved and maintained confirmed HIV-1 RNA <50 copies/mL. The mean increase from baseline in CD4 cell count was 263 cells/mm³ for the VIREAD arm and 283 cells/mm³ for the stavudine arm.

Through 144 weeks, 12 patients in the VIREAD group and 9 patients in the stavudine group experienced a new CDC Class C event.

The proportion of patients who achieved and maintained confirmed HIV RNA <400 copies/mL using intent-to-treat analysis at Weeks 24, 48, 96 and 144 in Study 903 are presented in Table 23.

Table 23. Virologic Response Through Week 144, Study 903*^†

Study Week

Proportion of Patients with HIV-1 RNA

< 400 copies/mL (%)

VIREAD + 3TC +

EFV

(N=299)

Stavudine + 3TC + EFV

(N=301)

Week 24 86 86

Study Week

Proportion of Patients with HIV-1 RNA

< 400 copies/mL (%)

VIREAD + 3TC +

EFV

(N=299)

Stavudine + 3TC + EFV

(N=301)

Week 48 79 82

Week 96 74 70

Week 144 68 62

* Roche Amplicor HIV-1 Monitor Test

† Responders at each visit are patients who had achieved and maintained HIV-1 RNA <400 copies/mL without discontinuation by that visit.

Study 934 - VIREAD + Emtricitabine + Efavirenz Compared with Lamivudine/Zidovudine + Efavirenz: Treatment outcomes through 48 and 144 weeks for those patients who did not have efavirenz resistance at baseline are presented in Table 24.

Table 24. Outcomes of Randomized Treatment at Weeks 48 and 144

(Study 934)

Outcome

At Week 144¹

3TC/AZT +

EFV

(N=229)

Responder²

58%

Virologic failure³

6%

Rebound

5%

Never suppressed

0%

Change in antiretroviral

regimen

1%

Death

1%

Discontinued due to adverse event

12%

Discontinued for other reasons⁴

22%

1 Patients who were responders at Week 48 or Week 96 but did not consent to continue study after Week 48 or Week 96 were excluded from analysis.

2 Patients achieved and maintained confirmed HIV-1 RNA <400 copies/mL through Week 48. 3 Includes confirmed viral rebound and failure to achieve confirmed <400 copies/mL through Week 48. 4 Includes lost to follow-up, patient withdrawal, non-compliance, protocol violation and other reasons.

In this study, VIREAD + emtricitabine in combination with efavirenz showed statistically significant superiority over lamivudine/zidovudine in combination with efavirenz in

achieving and maintaining HIV-1 RNA <400 copies/mL through 48 weeks and 144 weeks (Table 24). The difference in the percentages of responders, stratified by baseline CD4 cell count (< or ≥200 cells/mm³), between the VIREAD + emtricitabine group and the lamivudine/zidovudine group was 11.4%, and the 95% CI was 4.3% to 18.6% (p=0.002) at Week 48 and was 13% at Week 144, 95% CI=4% to 22% (p=0.004). Through 48 weeks of therapy, 80% and 70% of patients in the VIREAD + emtricitabine and the lamivudine/zidovudine arms, respectively, achieved and maintained HIV-1 RNA <50 copies/mL (64% and 56%, respectively, through Week 144). The difference in the percentages of responders, stratified by baseline CD4 cell count (< or ≥200 cells/mm³), between the VIREAD + emtricitabine group and the lamivudine/zidovudine group was 9.1%, and the 95% CI was 1.6% to 16.6% (p=0.021) at Week 48 and was 8% at Week 144, 95% CI = −1% to 17% (p=0.082). The mean increase from baseline in CD4 cell count was 190 cells/mm³ for the VIREAD + emtricitabine + efavirenz arm, and 158 cells/mm³ for the lamivudine/zidovudine + efavirenz arm (p=0.002) at Week 48 (312 and 271 cells/mm³, respectively, at Week 144, p=0.089). Through 48 weeks, 7 patients in the VIREAD + emtricitabine group and 5 patients in the lamivudine/zidovudine group experienced a new CDC Class C event (10 and 6 patients, respectively, through 144 weeks).

The difference in the proportion of patients who achieved and maintained HIV-1 RNA <400 copies/mL through 48 weeks largely results from the higher number of discontinuations due to adverse events and other reasons in the zidovudine/lamivudine group in this open label study.

Adolescent Patients

In Study 321, 87 treatment-experienced patients 12 to <18 years of age were treated with VIREAD (N=45) or placebo (N=42) in combination with an optimized background regimen (OBR) for 48 weeks. The mean baseline CD4 cell count was 374 cells/mm³ and the mean baseline plasma HIV-1 RNA was 4.6 log₁₀ copies/mL. The median time-weighted average changes from baseline in plasma HIV-1 RNA at Weeks 24 (DAVG₂₄) and 48 (DAVG₄₈) were −1.58 and −1.42 log₁₀ copies/mL for the VIREAD group compared to −1.55 and −1.35 log₁₀ copies/mL for the placebo group, at Weeks 24 and 48, respectively. The lack of difference in virological response between the two groups was primarily attributable to greater activity of the OBR in the placebo group compared to the VIREAD group.

Genotypic Analyses of VIREAD in Patients with Previous Antiretroviral Therapy (Studies 902 and 907)

The virologic response to VIREAD therapy has been evaluated with respect to baseline viral genotype (N=222) in treatment-experienced patients participating in trials 902 and 907. In both of these studies, 94% of the participants evaluated had baseline HIV isolates expressing at least one NRTI mutation. These included resistance mutations associated with zidovudine (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N), the

lamivudine/abacavir-associated mutation (M184V), and others. In addition the majority of participants evaluated had mutations associated with either protease inhibitor or non-nucleotide reverse transcriptase inhibitor use. Virologic responses for patients in the genotype sub-study were similar to the overall results in Studies 902 and 907.

Several exploratory analyses were conducted to evaluate the effect of specific mutations and mutational patterns on virologic outcome.

Reduced responses to VIREAD were observed in patients with pre-existing zidovudine-associated mutations and appeared to depend on the number of specific mutations. VIREAD-treated patients whose HIV expressed 3 or more zidovudine-associated mutations that included either the M41L or L210W reverse transcriptase mutation showed reduced responses to VIREAD therapy; however, these responses were still improved compared with placebo. The presence of the D67N, K70R, T215Y/F, or K219Q/E/N mutation did not appear to affect responses to VIREAD therapy.

In the protocol defined analyses, virologic response to VIREAD was not reduced in patients with HIV that expressed the lamivudine/abacavir-associated M184V mutation. In the absence of zidovudine-associated mutations, patients with the M184V mutation receiving VIREAD showed a −0.84 log₁₀ copies/mL decrease in their HIV-1 RNA relative to placebo. In the presence of zidovudine-associated mutations, the M184V mutation did not affect the mean HIV RNA responses to VIREAD treatment. HIV-1 RNA responses among these patients were durable through Week 48.

There were limited data on patients expressing some primary nucleoside reverse transcriptase inhibitor mutations and multi-drug resistant mutations at baseline. However, patients expressing mutations at K65R (N=6), or L74V without zidovudine-associated mutations (N=6) appeared to have reduced virologic responses to VIREAD.

The presence of at least one HIV protease inhibitor or non-nucleoside reverse transcriptase inhibitor mutation at baseline did not appear to affect the virologic response to VIREAD. Cross-resistance between VIREAD and HIV-1 protease inhibitors is unlikely because of the different enzyme targets involved.

In treatment-experienced patients, 14 of 304 (4.6%, studies 902 and 907) isolates from patients failing VIREAD at 96 weeks showed >1.4 fold (median: 2.7) reduced susceptibility to tenofovir. Genotypic analysis of the resistant isolates showed a mutation in the HIV-1 RT gene resulting in the K65R amino acid substitution.

Phenotypic Analyses of VIREAD in Patients with Previous Antiretroviral Therapy (Studies 902 and 907)

The virologic response to VIREAD therapy has been evaluated with respect to baseline phenotype (N=100) in treatment-experienced patients participating in trials 902 and 907. Phenotypic analysis of baseline HIV from patients in Studies 902 and 907 demonstrated a correlation between baseline susceptibility to VIREAD and response to VIREAD therapy. Table 25 summarizes the HIV-1 RNA response by baseline VIREAD susceptibility.

Table 25. HIV-1 RNA Response at Week 24 by Baseline VIREAD

Susceptibility (Intent-To-Treat)¹

Baseline VIREAD Susceptibility² Change in HIV-1 RNA³ (N)

≤1 –0.74 (35)

>1 and ≤3 –0.56 (49)

>3 and ≤4 –0.3 (7)

≤4 –0.61 (91)

>4 –0.12 (9)

1 Tenofovir susceptibility was determined by recombinant phenotypic Antivirogram™ assay (Virco). 2 Fold change in susceptibility from wild-type.

3 Average HIV-1 RNA change from baseline through Week 24 (DAVG₂₄) in log₁₀ copies/mL.

Genotypic Analyses of VIREAD in Antiretroviral-Naïve Patients

Genotypic analyses of patients with virologic failure showed development of efavirenz-associated and lamivudine-associated mutations to occur most frequently and with no difference between the treatment arms (Study 903). The K65R mutation occurred in 8 patients on the VIREAD arm and in 2 patients on the stavudine arm. Of the 8 patients who developed K65R in the VIREAD arm through 144 weeks, 7 of these occurred in the first 48 weeks of treatment and 1 at Week 96. One patient in the VIREAD arm developed the K70E substitution in their virus. Among these patients, 5/8 patients subsequently gained full virologic control (<50 copies/mL) upon switching to new regimens that included a protease inhibitor in combination with nucleoside reverse transcriptase inhibitors through a median of 155 weeks of follow-up. From both genotypic and phenotypic analyses there was no evidence for other pathways of resistance to VIREAD.

In Study 934 (VIREAD + emtricitabine + efavirenz compared with

lamivudine/zidovudine + efavirenz), resistance analysis was performed on HIV isolates from all patients with >400 copies/mL of HIV-1 RNA at Week 144 or early discontinuation. Genotypic resistance to efavirenz, predominantly the K103N substitution, was the most common form of resistance that developed. Resistance to efavirenz occurred in 13 of 19 (68%) analyzed patients in the VIREAD + EMTRIVA group and in 21 of 29 (72%) analyzed patients in the lamivudine/zidovudine group. The M184V substitution, associated with resistance to EMTRIVA and lamivudine, was observed in 2 of 19(11%) analyzed patients in the VIREAD + emtricitabine group and in 10 of 29 (34%) analyzed patients in the lamivudine/zidovudine group.

In treatment-naïve patients treated with VIREAD + emtricitabine + efavirenz, none of the HIV isolates from 19 patients analyzed for resistance showed reduced susceptibility to tenofovir or the presence of the K65R or K70E substitution.

In Study 321 (adolescent patients 12 to <18 years) (see CLINICAL TRIALS), HIV-1 isolates from 43 patients who had plasma HIV-1 RNA ≥400 copies/mL were evaluated for

tenofovir resistance-associated substitutions. One patient developed the K65R substitution by Week 48.

Clinical Efficacy in Patient with HBV

Study Demographics and Trial Design

HBeAg-Negative Chronic Hepatitis B: Study 0102 was a Phase 3, randomized, double-blind, active-controlled study of VIREAD 300 mg compared to HEPSERA 10 mg in 375 HBeAg- (anti-HBe+) patients, the majority of whom were nucleoside-naïve. The mean age of patients was 44 years, 77% were male, 25% were Asian, 65% were Caucasian, 17% had previously received alpha-interferon therapy and 18% were nucleoside-experienced (16% had prior lamivudine experience). At baseline, patients had a mean Knodell necroinflammatory score of 7.8; mean plasma HBV DNA was 6.9 log₁₀ copies/mL; and mean serum ALT was 140 U/L.

HBeAg-Positive Chronic Hepatitis B: Study 0103 was a Phase 3, randomized, double-blind, active-controlled study of VIREAD 300 mg compared to HEPSERA 10 mg in 266 (HBeAg+) nucleoside-naïve patients. The mean age of patients was 34 years, 69% were male, 36% were Asian, 52% were Caucasian, and 16% had previously received alpha-interferon therapy. At baseline, patients had a mean Knodell necroinflammatory score of 8.4; mean plasma HBV DNA was 8.7 log₁₀ copies /mL; and mean serum ALT was 147 U/L.

The primary data analysis was conducted after all patients reached 48 weeks of treatment.

Table 26. Studies 0102 and 0103: VIREAD Compared to HEPSERA

Study No.

Gender

GS-US-174 -0102

Male: 77% Female:

23%

Study No.

Gender

GS-US-174 -0103

Male: 69% Female:

31%

Study Results

Experience in Patients with Compensated Liver Disease at 48 weeks: In HBeAg- and HBeAg + patients VIREAD was shown to be statistically superior with respect to the primary efficacy endpoint (complete response to treatment). VIREAD was associated with significantly greater proportions of patients with HBV DNA <400 copies/mL when compared to HEPSERA as shown in Table 27.

In Study 0103, a significantly greater proportion of patients in the VIREAD group had normalized ALT and achieved HBsAg loss, when compared to HEPSERA.

Table 27. Histological, Virological, Biochemical and Serological Response at

Week 48 (Studies 0102 and 0103)

0103 (HBeAg+)

HEPSERA (N=90)

Complete

Response (%) ^a

12

Histology

Histological Response (%)^b

68

HBV DNA (%) < 400 copies/mL (< 69 IU/mL)

13

ALT(%)

Normalized ALT^c

54

Serology (%) HBeAg Loss/ Seroconversion

HBsAg Loss/ Seroconversion

* p value vs adefovir dipivoxil < 0.001

** p value vs adefovir dipivoxil < 0.05

a Complete response defined as HBV DNA levels < 400 copies/ml and Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis.

b Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis c The population used for analysis of ALT normalization included only patients with ALT above ULN at baseline.

VIREAD was associated with significantly greater proportions of patients with undetectable HBV DNA (<169 copies/mL[<29 IU/mL]; the limit of quantification of the Roche Cobas Taqman HBV assay), when compared to HEPSERA (Study 0102; 91%, 56%, p <0.001 and Study 0103; 69%, 9%, p <0.001), respectively.

Response to treatment with VIREAD was comparable in nucleoside-experienced (N=51) and nucleoside-naive (N=375) patients and in patients with normal ALT (N=21) and abnormal ALT (N=405) at baseline when Studies 0102 and 0103 were combined. Forty-nine of the 51 nucleoside-experienced patients were previously treated with lamivudine. Seventy-three percent of nucleoside-experienced and 69% of nucleoside-naive patients achieved complete response to treatment; 90% of nucleoside-experienced and 88% of nucleoside-naive patients achieved HBV DNA suppression <400 copies/mL. All patients with normal ALT at baseline and 88% of patients with abnormal ALT at baseline achieved HBV DNA suppression <400 copies/mL.

In Study ACTG 5127, a randomized, 48-week double-blind, controlled trial of VIREAD 300 mg in patients co-infected with HIV-1 and chronic hepatitis B with prior lamivudine

experience (90% of patients were lamivudine resistant), the mean serum HBV DNA level at baseline in patients randomized to the VIREAD arm was 9.45 log₁₀ copies/mL (N=27). Treatment with VIREAD was associated with a mean change in serum HBV DNA from baseline, in the patients for whom there was 48 week data, of −5.74 log₁₀ copies/mL (N=18). In addition, 61% of patients had normal ALT at Week 48.

Experience in Patients with Persistent Viral Replication at 48 weeks: Study 0106 was a double-blind, randomized study in which 53 nucleoside-experienced patients with persistent viral replication after receiving 24−96 weeks of treatment with HEPSERA were randomized to VIREAD monotherapy. Of these, 81% had HBV DNA <400 copies/mL, 75% had undetectable DNA (<169 copies/mL [<29 IU/mL]) and 41% had ALT normalization at Week

48.

Experience in Patients with Decompensated Liver Disease at 48 weeks: Study 0108 was a randomized, double-blind, active-controlled study evaluating the safety and efficacy of VIREAD (N=45) in patients with decompensated liver disease. Patients had a mean Child-Pugh-Turcotte (CPT) score of 7, mean HBV DNA of 5.8 log₁₀ copies/mL and mean serum ALT of 61 U/L at baseline. Forty-two percent (19/45) of patients had at least 6 months of prior lamivudine experience and 9 of 45 patients (20%) had lamivudine and/or adefovir resistance substitutions at baseline.

The coprimary safety endpoints were discontinuation due to an adverse event and confirmed increase in serum creatinine ≥0.5 mg/dL or confirmed decrease in serum phosphorus of <2 mg/dL.

In the VIREAD treatment arm, 3 of 45 patients (7%) discontinued treatment due to an adverse event; 4 of 45 patients (9%) experienced a confirmed increase in serum creatinine of ≥0.5 mg/dL or confirmed decrease in serum phosphorus of <2 mg/dL through Week 48. HBV DNA <400 copies/mL and normal ALT were observed in 31 of 44 patients (70%) and 25 of 44 patients (57%), respectively. The mean change from baseline in CPT score was −1; the mean absolute CPT score was 6 at Week 48.

Experience Beyond 48 weeks: In Studies 0102 and 0103 patients who completed 48 weeks of double-blind treatment with either VIREAD or HEPSERA rolled over with no interruption in treatment to open-label VIREAD. In Studies 0102 and 0103, 93% and 89% of the randomized and treated patients entered the open-label study, respectively. In Study 0102, 90% and 88% of patients who were randomized to VIREAD and HEPSERA, respectively, completed 96 weeks of treatment and in Study 0103, 82% and 92% of patients who were randomized to VIREAD and HEPSERA, respectively, completed 96 weeks of treatment. In Studies 0102 and 0103, 84% and 73% of patients who entered the open-label phase continued in the study through to Week 288, respectively. At both Week 96 and Week 288, viral suppression, biochemical and serological responses were in general maintained with continued VIREAD treatment. In patients rolling over from HEPSERA to VIREAD at Week 48, HBV DNA rapidly declined in HEPSERA non-responders (HBV DNA ≥400 copies/ml at Week 48) and was maintained below 400 copies/ml in HEPSERA responders (HBV DNA <400 copies/ml at Week 48) (see Table 28).

Table 28. Virological, Biochemical and Serological Response at Week 96 and

Week 288 (Studies 0102 and 0103)

Outcomes^a

0103 (HBeAg+)

HEPSERA Rollover to VIREAD^f

(N=90)

96 weeks^c

288 weeks^e

HBV DNA < 400 copies/mL

[<69 IU/mL]

78%

Week 48 HEPSERA Responder^g

100%

Week 48 HEPSERA Non-responder^h

100%

HBV DNA < 169 copies/mL

[<29 IU/mL]

78%

ALT

Normalized ALTⁱ

70%

Serology

HBeAg Loss/ Seroconversion

41%/

33%

HBsAg Loss/ Seroconversion

10%/

8%^k a Based on Long-Term Evaluation algorithim (LTE-ITT Analysis) - patients who discontinued the study at any time prior to Week 288 due to a protocol defined endpoint, as well as those completing Week 288, are included in the denominator. The LTE-ITT Analysis includes data for subjects who added FTC 200 mg once daily to their open-label VIREAD regimen at or beyond Week 72.

b 48 weeks double-blind VIREAD followed by up to 48 weeks open-label VIREAD.

c 48 weeks double-blind HEPSERA followed by up to 48 weeks open-label VIREAD. d 48 weeks double-blind VIREAD followed by up to 240 weeks open-label VIREAD.

e 48 weeks double-blind HEPSERA followed by up to 240 weeks open-label VIREAD. f At the discretion of the clinician, patients with HBV DNA ≥400 copies/mL at Week 72 or later could receive intensification therapy with open label TDF + 200 mg emtricitabine (administered as fixed dose combination TRUVADA).

g Patients treated with HEPSERA for 48 weeks whose HBV DNA <400 copies/mL based on observed (missing = excluded) data (Study 0102, N=68; Study 0103, N=7)

h Patients treated with HEPSERA for 48 weeks whose HBV DNA ≥400 copies/mL based on observed (missing = excluded) data (Study 0102, N=29; Study 0103, N=56)

i The population used for analysis of ALT normalization included only patients with ALT above ULN at baseline. j One patient had confirmed HBsAg loss through Week 288 and remains in the treatment-free follow-up period. k Cumulative percentages based upon a Kaplan Meier analysis (KM-ITT)

NA = Not Applicable.

Paired baseline and Week 240 liver biopsy data were available for 348/489 patients who remained in Studies 0102 and 0103 (Table 29). Ninety-five percent (240/252) of patients without cirrhosis at baseline and 99% (95/96) of patients with cirrhosis at baseline had either no change or an improvement in fibrosis (Ishak fibrosis score). Of the 96 patients with cirrhosis at baseline (Ishak fibrosis score 5−6), 25% (24) experienced no change in Ishak fibrosis score and 73% (70) experienced regression of cirrhosis by Week 240 with a reduction in Ishak fibrosis score of at least 2 points.

Table 29. Histological Response (%) in Compensated HBeAg Negative and

HBeAg Positive Subjects at Week 240 Compared to Baseline

Study 0103 (HBeAg+)

HEPSERA Rollover to VIREAD

N=90^d

Histological

Response^a,b (%)

90 [43/48]

a The population used for analysis of histology included only patients with available liver biopsy data (Missing =

Excluded) by Week 240. Response after addition of emtricitabine is included (total of 17 subjects across both studies). b Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis score. c 48 weeks double-blind TDF followed by up to 192 weeks open-label TDF.

d 48 weeks double-blind adefovir dipivoxil followed by up to 192 weeks open-label TDF.

Patients with Lamivudine-Resistant Chronic Hepatitis B: Study GS-US-174-0121 explored the safety and efficacy of VIREAD (TDF 300 mg) compared to an unapproved antiviral regimen [TRUVADA (FTC 200 mg/TDF 300 mg)] in subjects with CHB, viremia (HBV DNA ≥1,000 IU/mL), and genotypic evidence of lamivudine resistance (rtM204I/V +/- rtL180M).

After 96 weeks of treatment, 126 of 141 subjects (89%) and 120 of 139 subjects (86.3%) randomized to VIREAD and to the comparator, respectively, had HBV DNA <400 copies/mL, and 49 of 79 subjects (62%) randomized to VIREAD had ALT normalization. Among the HBeAg-positive subjects randomized to VIREAD, 10 of 65 subjects (15%) experienced HBeAg loss, and 7 of 65 subjects (11%) experienced anti-HBe seroconversion through Week 96.

Genotypic Analyses of VIREAD in Patients with HBV (Studies 0102, 0103, 0106 and 0108)

A cumulative genotypic resistance analysis of subjects in Studies GS-US-174-0102 and GS-US-174-0103 who received at least 24 weeks of VIREAD monotherapy and remained viremic (HBV DNA ≥400 copies/mL) at the last evaluable study visit on VIREAD monotherapy was performed. Of the 612 subjects who received at least 24 weeks of VIREAD monotherapy, 57 (9.3%) were viremic with up to 288 weeks of cumulative treatment with VIREAD monotherapy. Overall, no amino acid substitutions in the HBV polymerase were associated with resistance to VIREAD (genotypic or phenotypic analyses). Genotypic data from paired baseline and on-treatment isolates were available for 49/57 subjects. The majority of subjects (33 of 57, 58%) had no change in their HBV polymerase compared to the baseline isolate, 12 of 57 (21%) had polymorphic site changes, and 4/57 (7%) had conserved site changes.

In Study 0106, 53 patients (including 15 patients with adefovir or lamivudine resistance substitutions at baseline) received VIREAD for 48 weeks. Genotypic data from paired baseline and on treatment HBV isolates were available for 15 of 17 patients with HBV DNA >400 copies/mL at Week 48. No amino acid substitutions associated with resistance to VIREAD were identified in these isolates.

In Study 0108, 45 patients (including 9 patients with lamivudine and/or adefovir resistance substitutions at baseline) received VIREAD for up to 48 weeks. Genotypic data from paired baseline and on treatment HBV isolates were available for 6 of 8 patients with HBV DNA >400 copies/mL. No amino acid substitutions associated with resistance to VIREAD were identified in these isolates.

In Study 0121, 141 patients with lamivudine resistance substitutions at screening received treatment with VIREAD for up to 96 weeks. Genotypic data from paired baseline and on treatment HBV isolates were available for 6 of 9 patients with HBV DNA >400 copies/mL at their last time point on VIREAD. No amino acid substitutions associated with resistance to VIREAD were identified in these isolates.

VIROLOGY (MICROBIOLOGY)

Activity in HIV-1

Tenofovir diphosphate inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.

Anti-HIV Activity In Vitro

The in vitro antiviral activity of tenofovir against laboratory and clinical isolates of HIV was assessed in lymphoblastoid cell lines, primary monocyte/macrophage cells and peripheral blood lymphocytes. The IC₅₀ (50% inhibitory concentrations) for tenofovir was in the range

of 0.04 μM to 8.5 μM. In drug combination studies of tenofovir with nucleoside and non-nucleoside analog inhibitors of HIV reverse transcriptase, and protease inhibitors, additive to synergistic effects were observed. In addition, tenofovir has also been shown to be active in vitro against HIV-2, with similar potency as observed against HIV-1.

In Vitro Resistance

HIV isolates with reduced susceptibility to tenofovir have been selected in vitro. These viruses expressed a K65R substitution in reverse transcriptase and showed a 2–4-fold reduction in susceptibility to tenofovir. In addition, a K70E substitution in HIV-1 reverse transcriptase has been selected by tenofovir and results in low-level reduced susceptibility to tenofovir.

In Vitro Cross-Resistance

Cross-resistance among certain reverse transcriptase inhibitors has been recognized. The K65R and K70E substitutions results in reduced susceptibility to abacavir, didanosine, emtricitabine, lamivudine, and tenofovir. The in vitro activity of tenofovir against HIV-1 strains with zidovudine-associated reverse transcriptase mutations (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N) was evaluated. Zidovudine-associated mutations may also confer reductions in susceptibility to other nucleoside reverse transcriptase inhibitors (NRTIs) and these mutations have been reported to emerge during combination therapy with stavudine and didanosine. In 20 samples that had multiple zidovudine-associated mutations (mean 3.3), a mean 3.1-fold increase of the IC₅₀ of tenofovir was observed (range 0.8–8.4). Multinucleoside resistant HIV-1 with a T69S double insertion mutation in the reverse transcriptase showed reduced susceptibility to tenofovir. Tenofovir showed slightly increased activity against HIV-1 expressing the M184V resistance mutation.

Activity in HBV

Anti-Hepatitis B Virus Activity In Vitro

The in vitro antiviral activity of tenofovir against HBV was assessed in the HepG2 2.2.15 cell line. The EC₅₀ values for tenofovir were in the range of 0.14 to 1.5 μM, with CC₅₀ (50% cytotoxicity concentration) values >100 μM. Tenofovir diphosphate inhibits recombinant HBV polymerase with a Ki (inhibition constant) of 0.18 μM. In in vitro drug combination studies of tenofovir with nucleoside anti-HBV reverse transcriptase inhibitors lamivudine, telbivudine, and entecavir, additive anti-HBV activity was observed. Additive to slightly synergistic effects were observed with the combination of tenofovir and emtricitabine.

In Vitro Cross-Resistance

Cross-resistance has been observed among HBV reverse transcriptase inhibitors.

In cell based assays, HBV strains expressing the rtV173L, rtL180M, and rtM204I/V mutations associated with resistance to lamivudine and telbivudine showed a susceptibility to tenofovir ranging from 0.7 to 3.4-fold that of wild type virus.

HBV strains expressing the rtL180M, rtT184G, rtS202G/I, rtM204V and rtM250V mutations associated with resistance to entecavir showed a susceptibility to tenofovir ranging from 0.6 to 6.9-fold that of wild type virus.

HBV strains expressing the adefovir-associated resistance mutations rtA181V and rtN236T showed a susceptibility to tenofovir ranging from 2.9 to 10-fold that of wild type virus.

Viruses containing the rtA181T mutation remained susceptible to tenofovir with EC₅₀ values 1.5-fold that of wild type virus.

NON-CLINICAL TOXICOLOGY

The non-clinical safety profile of TDF has been studied in mice, rats, guinea pigs, rabbits, dogs, and monkeys. In all species, TDF was hydrolyzed to tenofovir following absorption. Tenofovir was cleared exclusively by renal elimination, without further metabolic changes, by a combination of glomerular filtration and tubular secretion.

Single Dose Toxicity

Following single doses, the no-effect-level (NOEL) in rats was 1500 mg/kg. Following single doses in dogs (270 mg/kg), mild renal tubular karyomegaly and/or basophilia were the only effects observed. Single oral doses of TDF had no adverse effects on the central nervous system (male rats, 50 or 500 mg/kg) or on cardiovascular and respiratory function (conscious male dogs, 30 mg/kg). An assessment of effects on renal function demonstrated increased urinary electrolyte excretion and urine volume in rats administered TDF 500 mg/kg; no effect was observed at 50 mg/kg. When rats were administered TDF (0, 50, or 500 mg/kg) to evaluate effects on the gastrointestinal transit of a charcoal meal, there was reduced gastric emptying at 500 mg/kg/day, but no effect at 50 mg/kg/day.

Subacute and Chronic Toxicity

The target organs of toxicity identified in the preclinical program were the gastrointestinal tract, renal tubular epithelium, and bone.

Gastrointestinal Tract

Gastrointestinal (GI) toxicity, observed primarily in rats, was dose related, reversible, and characterized by inflammation of the stomach and intestines, epithelial cytomegaly in the duodenum and jejunum, and villous atrophy of the ileum in rodents.

Kidney

Renal tubular epithelial karyomegaly, a morphologic change without pathologic consequence, was the most sensitive histological indicator of an effect on the kidney and was observed in rats, dogs, and monkeys. In dogs, the species most sensitive to effects on the kidney, additional microscopic alterations reported following chronic administration of TDF (≥10 mg/kg/day for 42 weeks) included individual cell necrosis, tubular dilatation, degeneration/regeneration, pigment accumulation, and interstitial nephritis. Associated biochemical changes in dogs administered TDF 30 mg/kg/day were a slight elevation in serum creatinine, glucosuria, proteinuria, and increased urine volume. The incidence and severity of nephrotoxicity was dose related.

Bone

Chronic administration of high doses of tenofovir or TDF in laboratory animals resulted in bone alterations. Minimal decreases in bone mineral density and content were observed in rats and dogs following oral administration of TDF at the doses of 300 and 30 mg/kg/day, respectively (6 and 10× human exposure, respectively). In juvenile monkeys pathologic osteomalacia and hypophosphatemia was observed following subcutaneous administration of tenofovir at the dose of 30 mg/kg/day (25× human exposure). Monkeys treated chronically with tenofovir 10 mg/kg/day, sc, (AUC = 4× humans), had no clinical or radiographic evidence of bone toxicity.

Bone changes in rats and dogs did not appear to consistently reverse during the recovery period; osteomalacia in juvenile monkeys was reversible.

Studies designed to evaluate the mechanism underlying effects on bone suggest that tenofovir may not have direct toxicity to bone. The mechanism is as yet unclear, however data suggest bone effects may be secondary to negative phosphate balance resulting from tenofovir-related reductions in intestinal phosphate absorption and/or renal reabsorption of phosphate.

Mutagenicity

TDF was equivocal in the in vitro bacterial mutation (Ames) assay (Salmonella-Eschericia coli/ Mammalian-Microsome Reverse Mutation Assay) but positive in the in vitro mouse lymphoma assay (L5178Y TK +/- Forward Mutation Assay), with and without metabolic activation. TDF was negative in the in vivo mouse micronucleus assay at plasma exposure levels of more than 10× the human exposure.

Reproductive Toxicity

Reproductive toxicity was evaluated in rats and rabbits. TDF had no adverse effects on fertility or general reproductive performance in rats at doses up to 600 mg/kg/day. TDF had no adverse effects on embryo-fetal development in rats at doses 450 mg/kg/day and in rabbits at doses up to 300 mg/kg/day. In a study of effects on peri- and postnatal development in rats, effects considered due to maternal toxicity (450–600 mg/kg/day) were reduced survival and a slight delay in sexual maturation in the F1 generation. There were no adverse effects

on growth, development, behavior, or reproductive parameters at non-maternally toxic doses (150 mg/kg/day).

Carcinogenicity

Long-term oral carcinogenicity studies were conducted in mice and rats receiving TDF. In the mouse study, (60/sex/group), one male and two female mice in the 600 mg/kg/day group (15 times the human systemic exposure at the recommended human dose of 300 mg/day) had duodenal tumors. The mechanism underlying this effect is uncertain but may relate to high local drug concentrations in the gastrointestinal tract. No treatment-related tumors were seen in mice in the 100 or 300 mg/kg/day groups. In the rat study (60/sex/group) at doses of 30, 100 and 300 mg/kg/day (approximately 5 times human exposure), no treatment-related increase in tumor incidence was observed.

REFERENCES

1. 1.

   Deeks, S. G., et al, Safety, Pharmacokinetics, and Antiretroviral Activity of

   Intravenous 9-{2-(R)-(Phosphonomethoxy)propyl}adenine, a Novel Anti-Human Immunodeficiency Virus (NIV) Therapy, in HIV-Infected Adults. Antimicrobial Agents and Chemotherapy, Sept. 1998, p. 2380-2384.

2. 2.

   Patricia Barditch-Crovo, Steven G. Deeks, Ann Collier, Sharon Safrin, Dion

   F. Coakley, Michael Miller, Brian P. Kearney, Rebecca L. Coleman, Patrick D. Lamy, James O. Kahn, Ian McGowan, Paul S. Lietman Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults, AAC, Oct 2001, Vol 45, No 10, p 2733-2739.

3. 3.

   Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS,

   Miller MD, Isaacson E, and Cheng AK (2002) Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. (16:9) pp 1257-1263.

4. 4.

   Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, and Miller

   MD (2002) Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS. (16:9) pp 1227-1235

5. 5.

   Study 903: Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman

   JMAH, Miller MD, Coakley DF, Lu B, Toole JJ, and Cheng AK. Efficacy and Safety of Tenofovir DF vs. Stavudine in Combination Therapy in Antiretroviral Naïve Patients: A 3 year Randomized Trial. (2004) JAMA. 292 (2): pp 191-201.

6. 6.

   Study 907: Squires K, Pozniak AL, Pierone G, Steinhart CR, Berger D, Bellos

   NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF and Cheng AK. (2003) Tenofovir DF in antiretroviral-experienced, nucleoside-resistant HIV-1 infected patients with incomplete viral suppression. Annals of Internal Medicine 139 (5): pp 313-320.

7. 7.

   Gallant, J.E., DeJesus, E., Arribas, J.R., Pozniak, A.L., Gazzard, B., Campo,

   R.E. et al. Tenofovir DF, Emtricitabine and Efavirenz versus Zidovudine, Lamivudine and Efavirenz for HIV. New Engl. J. Med. 2006 (354): 251-260.

8. 8.

   EMEA Public Statement, Efficacy and safety concerns regarding the co-administration of tenofovir disoproxil fumarate (TDF, Viread) and didanosine (ddI, Videx), 2005.

   http://www.emea.eu.int/pdfs/human/press/pus/6233105en.pdf.

9. 9.

   Podzamczer D, Ferrer E, Gatell JM, Niubo J, Dalmau D, Leon A, Knobel H,

   Polo C, Iniguez D, Ruiz I. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antiviral Therapy 2005; 10: 171-177.

10. 10.

    Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, et al.

    Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44 (5):1110-6.

11. 11.

    Benaboud, S., et al. 2011. Concentrations of Tenofovir and Emtricitabine in

    Breast Milk of HIV-1 Infected Women in Abidjan, Côte d’Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob. Agents Chemother. 55: 1315-1317.

    IMPORTANT: PLEASE READ

PART III. CONSUMER INFORMATION

^PrVIREAD^® (tenofovir disoproxil fumarate) tablets

This leaflet is Part III of a three-part “Product Monograph” published when VIREAD was approved for sale in Canada and is designed specifically for consumers. This leaflet is a summary and will not tell you everything about VIREAD. Contact your healthcare professional if you have any questions about the drug.

What the medication is used for:

• VIREAD is a type of medicine called a nucleotide analog

  reverse transcriptase inhibitor (NRTI).

• Use in the Treatment of HIV-Infection:

  VIREAD is a treatment for Human Immunodeficiency Virus (HIV) infection in adults and adolescents age 12 years and older and weighing at least 35 kg (77 lb). VIREAD is always used in combination with other anti-HIV medicines to treat people with HIV infection.

  HIV infection destroys CD4+ (T) cells, which are important to the immune system. After a large number of T cells are destroyed, acquired immune deficiency syndrome (AIDS) develops.

• Use in the Treatment of Chronic Hepatitis B:

  VIREAD is also used to treat chronic hepatitis B (an infection with hepatic B virus [HBV]) in adults age 18 years and older.

• If you have both HIV and HBV infection and are taking

  VIREAD, your healthcare professional should be prescribing VIREAD in combination with other anti-HIV medicines (See: Proper Use of This Medication).

What it does:

Treatment of HIV infection:

• In patients with HIV infection, VIREAD helps to block HIV

  reverse transcriptase (enzyme) that is needed for HIV to multiply. VIREAD lowers the amount of HIV in the blood (called viral load).

• VIREAD does not cure HIV infection or AIDS. The long-

  term effects of VIREAD are not known at this time. People taking VIREAD may still get opportunistic infections or other conditions that happen with HIV infection. Opportunistic infections are infections that develop because the immune system is weak.

  Treatment of Chronic Hepatitis B:

  • In patients with HBV infection, VIREAD works by interfering with the normal working of enzymes (HBV DNA polymerase) that are essential for the HBV virus to reproduce itself. VIREAD may help lower the amount of hepatitis B virus in your body by lowering the ability of the virus to multiply and infect new liver cells.
  • We do not know how long VIREAD may help your hepatitis. Sometimes viruses change in your body and medicines no longer work. This is called drug resistance.

VIREAD does not reduce the risk of passing HIV or HBV to others through sexual contact or blood contamination. Continue to practice safe sex and do not use or share dirty needles.

When it should not be used:

• Do not take VIREAD if you are allergic to VIREAD or any of its ingredients (See: What the important nonmedicinal ingredients are).

What the medicinal ingredient is:

tenofovir disoproxil fumarate (TDF)

What the important nonmedicinal ingredients are:

croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch.

What dosage forms it comes in:

VIREAD is available as tablets. Each tablet contains 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. The tablets are almond-shaped, light blue, film-coated, and debossed with “GILEAD” and “4331” on one side and with “300” on the other side.

ND PRECAUTIONS

Serious Warnings and Precautions

• The most serious possible side effect is harm to the kidneys, including damage to kidney cells, kidney tissue inflammation and kidney failure. Your healthcare professional may monitor your kidney function before beginning and while receiving VIREAD. Some patients treated with TDF (a component of VIREAD) have had kidney problems. Your healthcare professional may need to perform additional blood tests if you have had kidney problems in the past or need to take another drug that can cause kidney problems.

• If you have Hepatitis B Virus infection or if you have

  HIV and HBV infection together, “flare-ups” of Hepatitis B Virus infection, in which the disease suddenly returns in a worse way than before, can occur if you stop taking VIREAD. Do not stop taking VIREAD without your healthcare professional’s advice. If you stop taking VIREAD, tell your healthcare professional immediately IMPORTANT: PLEASE READ

about any new, unusual or worsening symptoms that you notice after stopping treatment. After you stop taking VIREAD, your healthcare professional will still need to check your health and take blood tests to check your liver for several months.

• The class of medicines to which VIREAD belongs (NRTIs)

  can cause a condition called lactic acidosis (build-up of acid in the blood). The symptoms that may be signs of lactic acidosis include: feeling very weak, tired or uncomfortable; unusual or unexpected stomach discomfort, feeling cold, feeling dizzy or lightheaded; suddenly developing a slow or irregular heartbeat. This rare but serious side effect has occasionally been fatal.

• Severe liver problems can happen in people who take

  VIREAD or similar medicines. You may develop an enlarged liver (hepatomegaly) or a fatty liver (steatosis). Non-specific symptoms such as yellowing of the skin and eyes, nausea, vomiting, and stomach pain might indicate the development of liver problems.

  Lactic acidosis or severe liver problems occur more often in women, particularly if they are very overweight. You should consult your healthcare professional immediately if such symptoms occur while you are receiving VIREAD. If you notice these symptoms, stop taking VIREAD and consult a healthcare professional immediately.

• TDF caused harm to the bones of animals. TDF reduced

  bone density in humans. If you notice bone pain, suffer a bone fracture, or other bone problem, consult your healthcare professional. If you have bone problems, you may wish to discuss calcium and/or vitamin D supplements with your healthcare professionals.

• Do not take VIREAD if you are already taking ATRIPLA^®,

  COMPLERA^®, DESCOVY^®, GENVOYA^®, ODEFSEY™, STRIBILD^®, TRUVADA^®, or VEMLIDY™ because these medicines contain the same or similar active ingredients.

• Do not take VIREAD if you have not already discontinued

  treatment with HEPSERA^®.

BEFORE you use VIREAD talk to your healthcare professional if:

• You are pregnant or planning to become pregnant:

  Pregnant mothers should not take VIREAD unless specifically directed by the healthcare professional. If you take VIREAD while you are pregnant, talk to your healthcare professional about how you can be included in the Antiviral Pregnancy Registry.

• You are breastfeeding or planning to breastfeed: Do not

  breastfeed if you are taking VIREAD. Tenofovir passes to your baby in your breast milk. You should not breastfeed because of the risk of passing HIV or HBV to your baby. Talk to your healthcare professional about the best way to feed your baby.

  • You have other medical conditions: Let your healthcare professional know if you have other medical conditions, especially hepatitis (inflammation of the liver), pancreatitis (inflammation of the pancreas), and bone and kidney problems.
  • You have HIV Infection.
  • You are taking other medicines: Some medicines can interact when taken together, including prescription and non-prescription medicines and dietary supplements. Other Special Warnings:

Your blood sugar levels (glucose) or levels of fats (lipids) in your blood may increase with HIV treatment. Your doctor may order blood tests for you.

INTERACTIONS WITH THIS MEDICATION

• Drugs that contain didanosine (Videx^®, Videx EC^®). TDF

  (VIREAD) may increase the amount of Videx in your blood. You may need to be followed more carefully if you are taking VIREAD and Videx together. Also, the dose of didanosine may need to be reduced.

• Reyataz^® (atazanavir sulfate), Kaletra^® (lopinavir/ritonavir),

  Prezista^® (darunavir), HARVONI^® (ledipasvir/sofosbuvir), EPCLUSA^® (sofosbuvir/velpatasvir), or VOSEVI™ (sofosbuvir/velpatasvir/voxilaprevir) may increase the amount of TDF (VIREAD) in your blood, which could result in more side effects. You may need to be followed more carefully if you are taking VIREAD together with Reyataz, Kaletra, Prezista, HARVONI, EPCLUSA, or VOSEVI. VIREAD may decrease the amount of Reyataz in your blood. If you are taking VIREAD and Reyataz together, you should also be taking Norvir^® (ritonavir).

PROPER USE OF THIS MEDICATION

Stay under a healthcare professional’s care when taking VIREAD. Do not change your treatment or stop treatment without first talking with your healthcare professional.

Carefully follow the directions and dosing schedule prescribed by your healthcare professional.

When your VIREAD supply starts to run low, see your healthcare professional for a refill. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to VIREAD and become harder to treat.

If you are taking VIREAD to treat your HIV or if you have HIV and HBV coinfection and are taking VIREAD, always take VIREAD in combination with other anti-HIV medicines. VIREAD and other products like VIREAD may be less likely to work in the future if you are not taking VIREAD with other anti-IMPORTANT: PLEASE READ

HIV medicines because you may develop resistance to those medicines.

If you have HBV only (without HIV), VIREAD can be prescribed as a single drug treatment for HBV.

Talk to your healthcare professional about taking an HIV test before you start treatment with VIREAD for chronic hepatitis B.

Only take medicine that has been prescribed specifically for you. Do not give VIREAD to others or take medicine prescribed for someone else.

Usual Adult Dose:

• The usual dose of VIREAD is one 300 mg tablet orally (by

  mouth) once a day.

• VIREAD may be taken with or without a meal.

Usual Adolescent (12 Years of Age and Older) Dose for HIV Infection:

• Body weight ≥35 kg (≥77 lb): Take one 300 mg VIREAD

  tablet once daily orally.

• VIREAD may be taken with or without a meal.

Overdosage:

In case of drug overdose, contact your healthcare professional, hospital emergency department or Regional Poison Control Centre, even if there are no symptoms.

Missed Dose:

• If you miss a dose of VIREAD, take it as soon as possible

  and then take your next scheduled dose at its regular time.

• Do not double the next dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

The most common side effects of VIREAD are:

• Diarrhea
• Nausea
• Vomiting
• Dizziness

Other side effects include:

• Flatulence (intestinal gas)

• Allergic reaction, including angioedema (swelling of the

  blood vessels) with symptoms such as skin rash, redness, swelling of the hands, legs, feet, face, lips, tongue or throat, with difficulty in breathing

• Stomach pain

  • Weakness
  • Inflammation of the pancreas
  • Shortness of breath
  • Headache
  • Rash

Changes in your immune system (Immune Reconstitution Inflammatory Syndrome) can happen when you start taking HIV medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time, or you could develop an autoimmune disease in which your immune system reacts against your own body [e.g. Grave's disease (which affects the thyroid gland), Guillain-Barré syndrome (which affects the nervous system) or polymyositis (which affects the muscles)] and it may develop at any time, sometimes months later after the start of HIV therapy. Sometimes symptoms can be severe, so if you develop high temperature (fever), joint or muscle pain, redness, rash, swelling or fatigue, or any new symptoms, contact your healthcare professional right away.

IMPORTANT: PLEASE READ

Lactic acidosis is a medical emergency and must be treated in the hospital. You may be more likely to get lactic acidosis or serious liver problems if you are very overweight (obese) or have been taking nucleoside analog medicines, like VIREAD, for a long time.

Muscle pain, muscle weakness, bone pain and softening of the bone (infrequently contributing to fractures) have also been reported.

This is not a complete list of side effects. For any unexpected side effects while taking VIREAD, contact your healthcare professional. TSTORE IT

HOW TO STORE IT

• Keep VIREAD and all other medications out of reach and sight of children.
• VIREAD should be stored at 15–30 °C (59–86 °F). It should remain stable until the expiration date printed on the label.
• Do not keep medicine that is out of date or that you no longer need. If you throw any medicines away, make sure that children will not find them.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

• Report online at www.canada.ca/en/health-

  canada/services/drugs-health-products/medeffect-canada

• Call toll-free at 1-866-234-2345

• Complete a Canada Vigilance Reporting Form and:

  • Fax toll-free to 1-866-678-6789, or

  • Mail to: Canada Vigilance Program Health Canada

    Postal Locator 1908C Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the Medeffect™ Canada Web site at www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.

NOTE: Should you require information related to the management of side effects, contact your healthcare professional. The Canada Vigilance Program does not provide medical advice.

IMPORTANT: PLEASE READ

This document plus the full Product Monograph, prepared for healthcare professionals, can be found at: www.gilead.ca or by contacting the sponsor, Gilead Sciences Canada, Inc., at: 1-866-207-4267

Gilead Sciences, Inc.

Foster City, CA 94404

USA

Gilead Sciences Canada, Inc.

Mississauga, ON

L5N 2W3

ATRIPLA^®, COMPLERA^®, DESCOVY^®, EMTRIVA^®, EPCLUSA^®, GENVOYA^®, HARVONI^®, HEPSERA^®, ODEFSEY™, SOVALDI^®, STRIBILD^®, TRUVADA^®, VEMLIDY™, VIREAD^®, and VOSEVI™ are trademarks of Gilead Sciences, Inc. or its related companies.

All other marks referenced herein are the property of their respective owners.

© 2018 Gilead Sciences, Inc. All rights reserved.

9427-G1318\2-23-0035